Evaluation of liposomal bismuth-ethanedithiol-tobramycin for treatment of cystic fibrosis pulmonary pseudomonas aeruginosa infection by Alhariri, Moayad Abdulaziz I.
  
 
EVALUATION OF LIPOSOMAL BISMUTH-ETHANEDITHIOL-TOBRAMYCIN FOR 
TREATMENT OF CYSTIC FIBROSIS PULMONARY PSEUDOMONAS AERUGINOSA 
INFECTION 
 
 
 
 
by 
 
 
 
Moayad Abdulaziz I. Alhariri 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of 
Master of Science (MSc) in Chemical Sciences 
 
 
 
 
 
 
 
 
The School of Graduate Studies 
Laurentian University 
Sudbury, Ontario, Canada 
 
 
 
 
 
 
 
 
 
 
 
© Moayad Alhariri, 2013 
THESIS DEFENCE COMMITTEE/COMITÉ DE SOUTENANCE DE THÈSE 
 
Laurentian Université/Université Laurentienne 
School of Graduate Studies/École des études supérieures 
 
Title of Thesis     
Titre de la thèse   EVALUATION OF LIPOSOMAL BISMUTH-ETHANEDITHIOL- 
    TOBRAMYCIN FOR TREATMENT OF CYSTIC FIBROSIS PULMONARY  
    PSEUDOMONAS AERUGINOSA INFECTION 
 
Name of Candidate   
Nom du candidat    Alhariri, Moayad Abdulaziz I. 
       
Degree                            
Diplôme                            Master of Science 
 
Department/Program    Date of Defence 
Département/Programme  Chemical Sciences  Date de la soutenance  September 20, 2013 
                                                       
APPROVED/APPROUVÉ 
 
Thesis Examiners/Examinateurs de thèse: 
                                                      
Dr. Abdel Omri  
(Supervisor/Directeur de thèse) 
 
Dr. Gustavo Arteca    
(Committee member/Membre du comité)    
       Approved for the School of Graduate Studies 
Dr. Hélène Joly      Approuvé pour l’École des études supérieures 
(Committee member/Membre du comité)   Dr. David Lesbarrères 
      M. David Lesbarrères 
Dr. Thien-Fah Mah    Director, School of Graduate Studies 
(External Examiner/Examinateur externe)  Directeur, École des études supérieures    
        
       
                                                                                                                                  
ACCESSIBILITY CLAUSE AND PERMISSION TO USE 
 
 
I, Moayad Abdulaziz I. Alhariri, hereby grant to Laurentian University and/or its agents the non-
exclusive license to archive and make accessible my thesis, dissertation, or project report in whole or in part in all 
forms of media, now or for the duration of my copyright ownership. I retain all other ownership rights to the 
copyright of the thesis, dissertation or project report. I also reserve the right to use in future works (such as articles 
or books) all or part of this thesis, dissertation, or project report. I further agree that permission for copying of this 
thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who 
supervised my thesis work or, in their absence, by the Head of the Department in which my thesis work was done. It 
is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be 
allowed without my written permission. It is also understood that this copy is being made available in this form by 
the authority of the copyright owner solely for the purpose of private study and research and may not be copied or 
reproduced except as permitted by the copyright laws without written authority from the copyright owner. 
iii 
 
Abstract 
The effectiveness of liposomes incorporating bismuth-ethanedithiol and loaded with 
tobramycin (LipoBiEDT-TOB) at sub-inhibitory concentrations to inhibit the production of 
quorum sensing signaling molecules and virulence factors induced by P. aeruginosa was 
evaluated in vitro.  In addition, we evaluated the efficacy and safety of free and encapsulated 
tobramycin in liposomal formulations administered intratracheally to rats chronically infected 
with P. aeruginosa. LipoBiEDT-TOB significantly reduced the production of quorum sensing 
signaling molecules and virulence factor secretion compared to free tobramycin. The 
LipoBiEDT-TOB formulation significantly reduced the bacterial count in lungs, modulated the 
IL-8 level in blood and minimized the nephrotoxicity that is associated with aminoglycoside 
treatment. These results support the hypothesis that aerosolization of liposomal aminoglycosides 
may enhance the management of chronic lung infections caused by resistant P. aeruginosa in 
patients with cystic fibrosis. 
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Chapter 1 
1. Introduction 
1.1. Cystic Fibrosis 
 Cystic fibrosis (CF), the most common autosomal recessive disorder, affects 1 in 2000 
Caucasians and results in shortening of the life span of the individual (1). [Please note that the 
references for chapter 1 are listed on page 97.] Cystic fibrosis is caused by a mutation in a single 
gene on the long arm of chromosome 7 that is responsible for encoding the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein (2). The CFTR is a multi-functional 
protein which is located on the apical membrane of epithelial cells. A defect in the CFTR 
function is responsible for CF-related multi-system injuries including the lungs, the endocrine 
system, the pancreas, the gastrointestinal tract and the reproductive system (3). However, 
pulmonary disease is the main cause of morbidity and mortality among the CF population due to 
persistent bacterial infection and inflammation (4).  
1.1.1. CFTR gene 
The CFTR gene is located on the long arm of chromosome 7. It is 25,000 base pairs long, 
contains 27 exons and encodes the CFTR protein which consists of 1480 amino acids. The 
severity of symptoms associated with CF and the rate of disease progression in organs depends 
on the type of mutation (5). The more than 1900 different mutations, that can cause CF with mild 
symptoms to serious problems, have been sorted into six classes, depending on their effect on 
CFTR protein production (6). The most common mutation is the loss of a phenylalanine residue 
at position 508, hence the name ΔF508, which causes severe disease in 70% of Caucasian CF 
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patients (7). This defective protein does not fold normally and consequently, the protein is unable 
to enter the Golgi apparatus to be expressed on the cell membrane. Retention and subsequent 
degradation of immature proteins in endoplasmic reticulum decreases the number of chloride 
channels which are responsible for transporting chloride ions (6). 
1.1.2. Structure of CFTR 
The CFTR protein is part of a larger family of adenosine-5-triphosphate (ATP) binding 
cassette transporters (8). It contains two ATP-hydrolysis domains, which are also called 
nucleotide-binding domains (NBDs), and two transmembrane domains (TMDs), each of them 
consisting of six membrane-spanning alpha helixes that form an anion channel (diagram 1). The 
NBDs are responsible for binding and hydrolysis of ATP which provides the required energy for 
channel activity. The activation of CFTR depends also on phosphorylation of the cytoplasmic R 
domain by cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA), and 
ATP to power a NBD for opening and closing the channel gate (9).  
 
Diagram 1: Illustration of the CFTR structure. 
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1.1.3. CFTR function in lungs 
The biological function of the CFTR protein can be understood by the observation that 
the sweat of CF patients contains high levels of electrolytes (10). The CFTR protein functions as 
a channel, across the membrane of secretory epithelial cells, to transport chloride ions (Cl
-
) in 
and out of the epithelial cells (11). It also down regulates trans-epithelial sodium (Na
+
) channels 
(8). The transport of Cl
-
 and inhibition of Na
+
 flux help to control the movement of water from 
the epithelial cells to the airways and vice versa, which is a necessary process for the production 
of a thin and freely-flowing mucus that protects the lungs from inhaled particles and pathogens 
(9). 
Mutation of the CFTR gene is the basic pathology of CF due to abnormal CFTR function 
and subsequent electrochemical alterations across the membrane and  dehydrated  mucus (12). 
The absence of the CFTR protein results in blocking the Cl
-
 secretion and increases epithelial 
sodium channel activity (ENaC), leading to an increased absorption of Na
+
 by the epithelial cells 
lining the airways (13). In addition, abnormally thick and sticky mucus accumulation prevents 
cilia to beat normally and thus cleanse an airway (14). Furthermore, the thick and sticky mucus 
becomes an ideal growth medium in the lungs for several pathogens such as Staphylococcus 
aureus, Haemophilus influenzae, Burkholderia cepacia and Pseudomonas aeruginosa (15). Here, 
we focus on the pathogenesis of P. aeruginosa due to the fact that this organism persists in the 
lungs of CF patients for the rest of their lives causing recurrent infection and inflammation (16). 
However, a complete discussion of the inflammation is beyond the scope of this thesis and those 
who are interested in CF inflammation can refer to recent review article by Cohen-Cymberknoh 
et al. (17). 
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1.2. Pseudomonas aeruginosa 
 P. aeruginosa is a Gram-negative bacillus found in water, soil, plants and hospital 
equipment (18). P. aeruginosa is categorized as an aerobic bacterium, but has the capability to 
grow in anaerobic conditions by using nitrogenous oxides such as nitrite (NO2¯) or nitrate 
(NO3¯) as respiratory electron acceptors (19, 20). This opportunistic human pathogen is 
responsible for a number of serious acute and chronic infections in patients with compromised 
immunity and mucosal defenses (21). The first step, to establish P. aeruginosa chronic lung 
infection in CF patients, involves the inhalation of P. aeruginosa from the surrounding 
environment. The bacteria basically attach to the upper respiratory tract and then gain access to 
the lung parenchyma because of a defect in the mucociliary cleansing mechanism in CF 
individuals (22, 23). P. aeruginosa expresses a variety of different surface ligands such as type 
IV pili which recognize epithelial cells’ receptors, in particular asialoganglioside (GM1) (24). P. 
aeruginosa adhesion can also be dependent on flagella that adhere to human respiratory mucin 
(25, 26). P. aeruginosa is also equipped with highly complex cell-to-cell signaling systems, 
known as quorum sensing, that control gene expression of virulence factors (27). 
1.2.1. Quorum sensing 
Quorum sensing (QS) is associated with a system of signaling molecules, known as 
autoinducers, that are produced and released by bacteria in response to bacterial cell density 
(diagram 2). P. aeruginosa does not express its virulence factors until it has adhered to, 
penetrated and proliferated in the epithelial cells in order to avoid the host immune response and 
to colonize the lung successfully (28). Ultimately, P. aeruginosa releases an excess of virulence 
factors which contribute to morbidity and mortality in the lungs of CF patients (29). P. 
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aeruginosa utilizes two homologues known as lasI/lasR and rhlI/rhlR which control synthesis of 
autoinducers and transcription activator proteins (30). lasI and rhlI synthesize LasI and RhlI 
proteins respectively. These proteins were subsequently identified as N-3-oxo-
dodecanoylhomoserine lactone (3O-C12-HSL) and N-butanoylhomoserine lactone (C4-HSL), 
respectively (31). As the P. aeruginosa cell density increases and the level of 3O-C12-HSL 
reaches a threshold concentration, 3O-C12-HSL binds to LasR. The 3O-C12-HSL/LasR complex 
then binds to promoters encoding several virulence factors such as lipase, chitinase, protease, and 
elastase (32-36). The 3O-C12-HSL/LasR also regulates the Pseudomonas quinolone system 
(PQS), a signaling molecule that is integral to the QS cascade. This signaling molecule functions 
as an additional regulatory link between the Las/Rhl QS circuits and regulates production of 
rhamnolipids, elastase, biofilm and pyocyanin production (37-39). The 3O-C12-HSL/LasR can 
also activate the second transcriptional regulatory rhlR. Once rhlR is activated, the synthesized 
protein RhlR binds to C4-HSL to activate expression of virulence factors such as alkaline 
protease, lectins A, lectins B and exoenzyme S (40, 41). 
6 
 
 
Diagram 2: Quorum sensing signaling molecules. A) Structure of acyl homoserine 
lactone; B) Pseudomonas quinolone system exploited for cell-to-cell communication 
by P. aeruginosa. 
 
1.2.2. Biofilm and secreted virulence factors 
Once P. aeruginosa colonizes the tissues successfully, it forms a biofilm and secretes a 
variety of virulence factors such as elastase, protease, and chitinase which participate in 
extensive tissue damage.  
1.2.2.1. Biofilms formation 
Biofilms are a structured community of bacterial cells surrounded by a self-produced 
polymeric matrix that can adhere to biotic and abiotic surfaces (42). It consists of 
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polysaccharides, DNA and other macromolecular components such as protein and lipid (42, 43). 
Bacteria develop the biofilm mode of growth in order to survive in a harsh environment and 
protect themselves from bactericidal challenges such as the host immune response (44, 45). 
Several steps are involved in developing mature biofilms including reversible attachment, 
irreversible attachment, multiplication, maturation of the biofilm to a mushroom-like structure 
(diagram 3). 
 Reversible attachment is initiated when P. aeruginosa binds to the GM1 through the 
flagella encoded by fliC (46). P. aeruginosa mutants deficient in flagella showed a significant 
decrease in the attachment and biofilm formation compared to flagellated strains (47). The 
irreversible attachment involves the loss of flagellum and expression of type IV pili that bind to 
GM1 (48). The type IV pili are also responsible for twitching motility and have been reported to 
have an important role in aggregation and microcolony formation. Bacteria also multiply and 
upregulate their genes’ expression such as algC, algD, and algU, which are responsible for 
extracellular synthesis (49). The last step in biofilm formation is the maturation of biofilms to 
mushroom-shaped structure, and it has been reported that QS plays a significant role in biofilm 
structural changes from a flat unstructured shape to a mushroom-shaped structure via the 
expression of more than 550 genes including other virulence factors (50). Studies showed that 
the increase in proteins, at this stage, correlates with a decrease in the oxygen levels at the stalk 
portion of the biofilm and a decrease in bacterial metabolic activities, whereas the cap portion of 
the mushroom-shaped biofilms tend to have a higher level of oxygen and bacterial metabolic 
activities (51, 52). Bacteria then disperse away from the interior portions of cell clusters and 
proceed to develop new biofilm. The dispersion process was shown to be synchronized with 
downregulation of gene expression; thereby it might suggest that dispersion and finding new 
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niche are an active process that the bacteria are programmed to undergo (50). Studies have 
shown that a biofilm in a hypotoxic environment is advantageous for bacterial survival in the 
host system because they limit antimicrobial penetration (53, 54). 
  
 
Diagram 3: Biofilms formation. Model of the development of a mature P. 
aeruginosa biofilm from planktonic cells. 
 
1.2.2.2. Elastases 
P. aeruginosa elastase is encoded by the lasB gene and its activity has been reported to 
play an important role in CF lung infection (55). It has been reported that elastase ruptures the 
respiratory epithelium via tight-junction destruction, thereby increasing epithelial permeability 
and facilitating recruitment of neutrophil (56, 57). Elastase also degrades several biological 
molecules including elastin, laminin, fibrin and collagen as well as surfactant proteins A and D 
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in the respiratory tract (58-60). Elastase is capable of cleaving the complementary components, 
interferon-γ and immunoglobulins, such as IgG and IgA (61, 62).  
1.2.2.3. Proteases 
Protease is an enzyme encoded by the lasA gene. LasA cleaves proteins into short 
fragments, preferentially at sites glycine-glycine-alanine sequence in the protein (63). LasA 
enhances the elastolytic activity of LasB elastase as well as human neutrophil elastase, leading to 
tissue destruction (64). LasA- or LasB-deficient mutants exhibit decreased invasion of epithelial 
cells in vivo as well as in cultured epithelial cells (65). Furthermore, protease plays an important 
role in P. aeruginosa pathogenesis through the so-called shedding process, which involves the 
cleavage of cell surface proteins, followed by the release of ectodomains from the cell surface. 
Ectodomains convert membrane-anchored growth factor receptors such as IL-6 into diffusible 
factors, membrane receptors to soluble competitors of their own ligand, and cell adhesion 
receptors into substances that are no longer capable of mediating interaction with other cells (66, 
67). P. aeruginosa seems to use the host shedding mechanism to increase its virulence (68). 
Beside the elastolytic activity of LasA, it also possesses a staphylolytic activity, which rapidly 
lyses S. aureus cells by cleaving the pentaglycine cross-links of bacterial cell wall peptidoglycan 
(69). 
1.2.2.4. Chitinases 
Chitin is the most abundant polysaccharide polymer found in nature (70). P. aeruginosa 
chitinase is encoded by the chiC gene and its chitin-binding protein is encoded by cbpD (71). 
Bacteria produce chitinase in the presence of chitin and repress its production when growing in a 
rich medium. Degradation of chitin requires two enzymatic steps; the breakdown of chitin into 
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disaccharide by chitinase followed by hydrolysis of the disaccharide to N-acetylglucosamine, 
which can be used by bacteria as an energy source (72).  
 
1.3. Treatment of P. aeruginosa infection 
A wide range of antibiotics including macrolides, β-lactams, and aminoglycosides have 
been developed to overcome P. aeruginosa infection (73-75). Combination therapy against P. 
aeruginosa has been recommended because of the concern that monotherapy might be associated 
with elevated levels of antimicrobial resistance (76). Aminoglycosides, however, are the drugs of 
choice in treatment of pulmonary infections caused by P. aeruginosa. 
1.3.1. Aminoglycosides 
1.3.1.1. Mechanism of action and toxicity 
 The most useful class of antibiotics for treating P. aeruginosa pulmonary infection in CF 
patients is that of aminoglycosides such as tobramycin (diagram 4) (77). Aminoglycosides 
contain amino sugars linked to an aminocyclitol ring or hexoses by a glycosidic bond (78). 
Aminoglycosides, including tobramycin, are water soluble, positively charged, and are poorly 
absorbed in the gastrointestinal tract, when delivered orally due to efflux of the drug by the P-
glycoprotein pump in the brush border of the small intestine (79, 80). Hence aminoglycosides are 
commonly administered intravenously or intratracheally to maintain high bioavailability (81). 
Inhalation of nebulized aminoglycosides (primarily tobramycin), in treating P. aeruginosa 
pulmonary infection, has advantages in providing a direct deposition of drug at the site of 
infection and reducing systemic exposure and toxic effects (82, 83). Aminoglycosides exert their 
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effect on bacteria by increasing cell membrane permeability via irreversible binding of 
aminoglycosides to divalent cations and inhibiting normal protein synthesis through binding to 
the highly conserved A-site of bacterial 16S subunit of 30S ribosomal RNA (rRNA) (84). This 
binding leads to disruption of the proofreading in the protein synthesis process, which results in 
the instability of the membranes, greater penetration of bactericidal agents and finally cell death 
(85). However, due to the high concentration and the long exposure to antibiotics required in 
treating pulmonary infection in CF, there has been toxicity associated with tobramycin including 
neuromuscular blockade, ototoxicity and nephrotoxicity (86-88). For example, the long-term use 
of high doses of conventional tobramycin leads to the accumulation of the drug within the renal 
proximal tubule and epithelial  lysosomes where it binds to phospholipids (89). By binding to the 
phospholipids myeloid bodies form causing deterioration of the tubular cells (90). Although 
nebulized antibiotic administration reduces these toxic effects, there are other problems 
associated with bacterial resistance to aminoglycosides.    
 
 
Diagram 4: Tobramycin structure. 
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1.3.1.2. Resistance of P. aeruginosa to aminoglycosides 
P. aeruginosa is among the most antibiotic resistant bacterial species that commonly 
causes infections (91). Several mechanisms have been reported for P. aeruginosa resistance to 
aminoglycoside antibiotics including enzymatic modification of the aminoglycoside, reduction in 
membrane permeability and up-regulation of the bacterial efflux system.  
Inactivation of aminoglycosides by P. aeruginosa-resistant strains is due to the enzymatic 
modification of the amino or hydroxyl groups of these antibiotics (92). Three groups of enzymes 
that are responsible on the drug modification in the bacteria cytoplasm have been identified 
(diagram 5); these are aminoglycoside phosphotransferases (APHs), aminoglycoside 
acetyltransferases (AACs), and aminoglycoside nucleotidyltransferases (ANTs). Phosphorylation 
of aminoglycosides is carried out by aminoglycoside phosphotransferases, utilizing adenosine 
triphosphate (ATP) as a substrate to phosphorylate the hydroxyl groups at positions 2'', 3', 3'', 4, 
6, 7'', and 9 (93-95). Aminoglycoside acetyltransferases belong to the GCN5-related N- 
acetyltransferases (GNAT) superfamily and catalyze the acetylation of the amino groups by 
utilizing coenzyme A as a substrate (96). Acetylation of aminoglycosides can occur with the 
amino groups located at positions 1, 2', 3, and 6' (92). Aminoglycoside nucleotidyltransferases 
mediate inactivation of aminoglycosides by utilizing ATP as a substrate and transferring 
adenosine monophosphate (AMP) to the hydroxyl group at positions 2'', 3'', 4', 6, and 9 of the 
aminoglycosides (97-100).  
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Diagram 5: Modification of tobramycin by aminoglycoside-modifying 
enzymes. (A) phosphorylation of tobramycin by aminoglycoside 
phosphotransferases; (B) acetylation of tobramycin by aminoglycoside 
acetyltransferases; and (C) adenylation of tobramycin by aminoglycoside 
nucleotidyltransferases. 
 
   Bacterial resistance to cationic antimicrobial agents is usually due to outer membrane 
impermeability resulting from lipopolysaccharide (LPS) modification (101). Poly-cationic 
antimicrobials competitively displace divalent cations which cross-link anionic LPS to 
destabilize the bacterial outer membrane, thereby promoting their own entry into the cell by a 
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process called self-promoted uptake (102). The interaction relies on the presence of phosphate 
groups at the lipid A domain (103). Bacteria such as P. aeruginosa modify their lipid A structure 
by adding polar groups such as 4-amino-4-deoxy-L-arabinose (Ara4N) (104). Ara4N neutralizes 
the negative charge of the phosphate residue, thereby decreasing bacterial susceptibility to 
cationic antimicrobials (105).  
 Resistance to multiple antimicrobials, including aminoglycoside antibiotics, in P. 
aeruginosa can be also explained by the involvement of the multidrug efflux system of the 
resistance-nodulation-division (RND) family, MexXY-OprM, which allows bacteria to get rid of 
the aminoglycoside antibiotics from the bacterial interior (106). The RND family of pumps 
generally comprises three components which include an inner membrane drug-proton antiporter 
encoded by mexY, an outer membrane channel-forming protein encoded by oprM, and a 
periplasmic membrane fusion protein encoded by mexX, which facilitates assembly and joins the 
other two components into a functional efflux pump (107). Expression of MexXY-OprM in P. 
aeruginosa has been shown to confer resistance to aminoglycosides (108). In order to restore 
aminoglycoside activity and counter bacterial resistance, combination therapy against P. 
aeruginosa has been recommended because of the concern that monotherapy might be associated 
with elevated levels of antimicrobial resistance (76). Recently, in vitro studies have found that 
combination bismuth-thiols with tobramycin possess a potent antimicrobial activity in treating 
Gram-negative bacteria (109). 
1.3.2. Bactericidal activity of bismuth agents 
Bismuth agents, such as bismuth subsalicylate and bismuth subcitrate (diagram 6), have 
antimicrobial activities against a wide variety of gastrointestinal tract infections caused by 
Escherichia coli, Vibrio cholera, and Helicobacter pylori. Bismuth components disrupt the cell 
15 
 
wall structure and inhibit secretion of virulence factors by H. pylori (110, 111). Biofilm 
production and adherence of Klebsiella pneumonia and H. pylori to epithelial cells are also 
reduced by bismuth agents (112, 113). However, bismuth subsalicylate and bismuth subcitrate 
alone or combined with antibiotics do not exhibit potent antibacterial activities against Gram-
negative bacteria such as P. aeruginosa (114, 115). One study reported an improvement in 
antimicrobial activity against P. aeruginosa by chelating bismuth to a lipophilic thiol which 
increases its solubility (diagram 7) (116). Furthermore, exposing P. aeruginosa to bismuth-
ethanedithiol at sub-inhibitory concentration showed reduction in alginate and biofilm 
production, as well as reduced adherence to epithelial cells. However, bismuth-ethanedithiol 
exhibited an increased toxicity on epithelial cells at concentrations that might be required to 
eliminate infection (117). Due to the toxicity of bismuth complexes and aminoglycoside 
antibiotics as well as increasing resistance of P. aeruginosa to currently available antibiotics, 
there is a strong demand for a carrier system such as liposomes which are safe on host cells and 
effective against bacterial infection. 
 
 
Diagram 6: Chemical structures of bismuth subsalicylate and bismuth subcitrate. 
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Diagram 7: Chemical structure of bismuth-ethanedithiol. 
 
1.4. Liposomes 
 Liposomes are spherical lipid vesicles ranging from nanometers to micrometers in size. They 
consist of one or more lipid bilayers surrounding an aqueous core. Liposomes are a relatively 
safe delivery system because they are biocompatible and biodegradable (118). There are several 
reasons for using liposomes as carriers for biologically active compounds. Currently, liposomes 
are designed to eliminate or reduce the toxicity of entrapped biologically active agents, to direct 
active agents to a desired delivery site, to protect the drug from unwanted metabolic breakdown, 
to improve the pharmacokinetics of the active agents and to increase their accumulation at the 
target site (119-121). They are usually classified into three categories (Diagram 8): small 
unilamellar vesicles (SUVs) or oligolamellar vesicles (OLVs), large unilamellar vesicles 
(LUVs), and multilamellar vesicles (MLVs) depending on their size and the number of bilayers 
present in the vesicle (122).  
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Diagram 8: Classification of liposomes by size. Multilamellar vesicles 
(MLVs), large unilamellar vesicles (LUVs) and small unilamellar vesicles 
(SUVs). 
 
There are a wide variety of liposomal applications because the physicochemical properties of 
liposomes can be modified by changing: i) the net surface charge; ii) pH sensitivity; iii) heat 
sensitivity; or iv) proportions and type of lipids in the formulation (Diagram 9). The ability of 
liposomes to encapsulate both hydrophilic and lipophilic agents has proven to be a highly 
valuable characteristic (123). Increased bacterial drug resistance to common therapies and the 
ability of some species to form drug-impermeable capsules and biofilms impermeable to 
antibiotics have become a major problem in modern medicine (124). Liposomes can introduce 
components with poor penetration such as antibiotics into bacterial cells such as those of P. 
aeruginosa (125). Intensive research is now focused on liposome-encapsulated antibiotics in 
order to enhance their pharmacokinetic properties and bactericidal activities, as well as reducing 
the drug’s adverse effects (123, 126). Due to the complex physicochemical properties of 
liposomes, there are many factors to consider when preparing a liposomal formulation, e.g., the 
different lipid compositions that constitute the liposome, as well as its size and surface charge 
will affect both the encapsulation efficiency (EE) and the release rate of the antibiotics. While 
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many investigators are making efforts to discover new antibiotics, others are focused on 
enhancing the efficacy of currently available antibiotics in the form of liposomal formulations 
(127-129). The present thesis work falls into the latter category.   
 
 
 
Diagram 9: Modification of the physicochemical properties of liposomes. (A) Neutral 
or charged, (B) lipid compositions, (C) long circulating, (D) immunoliposomes, (E) 
heat sensitive and (F) pH sensitive. DPPC, dipalmitoyl glycerophosphocholine; 
DMPC, dimyristoyl glycerophosphocholine; DSPC, distearoyl 
glycerophosphocholine; PHEA, poly(hydroxyethyl-L-asparagine); PHEG, 
poly(hydroxyethyl-L-glutamine); and PEG, polyethylene glycol. 
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1.5. Liposomes as a drug delivery system 
Liposomes have been successfully used in the delivery of anti-cancer, antibacterial and anti-
fungal drugs in vitro and in vivo. Developing liposomal formulations holds great interest in 
biomedical research because they may serve as a sustained drug release system (130), which 
results in prolonged half-life of the active agents. The extended half-life provided by liposomal 
formulation may lead to a decrease in frequency and length of drug administration (131, 132). 
Different methods of preparation and characterization, as well as the stability and interaction of 
liposomes with cells, are discussed in this section of the thesis. 
1.5.1. Methods of preparation 
There is a wide variety of liposomal methods that used in the preparation of liposomes fall 
into two main categories, i.e., conventional or mechanical methods. Conventional methods 
include the dehydration-rehydration vesicle, reverse-phase evaporation, injection, and detergent 
removal methods which all involve the dissolution of lipids in an organic phase followed by the 
addition of an aqueous solution. The mechanical methods, on the other hand, involve a 
mechanical force that results in a homogeneous mixture of liposomes.   
 1.5.1.1 Conventional methods 
1.5.1.1.1 Dehydration-rehydration method  
The dehydration-rehydration vesicle (DRV) method is the simplest and most widely used 
procedure for liposome preparation (127, 129). The process of preparing DRVs involves 
dissolution lipids in organic solvents such as chloroform or a chloroform/methanol mixture in a 
round bottom flask, followed by evaporating the organic phase to form a thin lipid film. The last 
20 
 
step in the preparation involves rehydration of the lipid film with an aqueous phase. When the 
dry lipid films are rehydrated, lipid lamellae are formed, mechanical agitation such as shaking or 
vortexing are used to detach the lipid film from the flask (133). The DRV technique has been 
employed by several laboratories. Halwani et al. (134) determined that liposomal formulation 
consisting of distearoyl glycerophosphocholine (DSPC) and cholesterol in a 2:1 molar ratio, 
encapsulated amikacin with an EE of 52.1 %. Another study investigated the encapsulation of 
ciprofloxacin in two cationic liposomal formulations that consisted of phosphatidylcholine (PC), 
cholesterol and N-(1-(2,3-dioleolyloxy)propyl)-N,N,N-trimethylammonium methyl sulphate 
(DOTAP) in a molar ratio of 3:4:3 or PC, dioleoylglycero-3-phosphoethanolamine (DOPE) and 
DOTAP in a molar ratio of 3:4:3 by DRV method (135). The EE of liposomal ciprofloxacin was 
67 % for PC/DOPE/DOTAP and 74 % for PC/cholesterol/DOTAP. 
1.5.1.1.2. Reverse-phase evaporation method  
Reverse-phase evaporation is a procedure for the preparation of liposomes with a large 
internal aqueous space. Preparation of reverse-phase evaporation vesicles (REV) results in large 
unilamellar and oligolamellar vesicles that are able to entrap large macromolecules with high EE 
(136). The procedure is based on two steps: adding an aqueous phase to form a phospholipid 
monolayer surrounded by water, and then adding an excess quantity of organic solvent. The lipid 
mixture is transferred into a round bottom flask and dissolved in a solvent, followed by removing 
the solvent under reduced pressure using a rotary evaporation, followed by flush-drying with 
nitrogen gas (137). The solvents that have been successfully used are diethyl ether, isopropyl 
ether, halothane and trifluorotrichloroethane. Lipids are then redissolved in the organic phase, 
followed by adding an aqueous solution of the bioactive agent. The solution is then sonicated to 
produce inverted micelles. The organic solvent is removed and a viscous, gel-like matrix forms. 
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As the majority of solvent has been removed, the gel collapses and an aqueous suspension of 
vesicles forms. The drawbacks to using REV method are the encapsulated drug is in contact with 
the organic phase exposed to mechanical agitation (133). Ciprofloxacin-loaded liposomes with 
different compositions and surface charge have been  prepared by REV (138). Positively charged 
liposomes exhibited the highest EE (82.01 %). The maximum amount of ciprofloxacin entrapped 
was achieved in liposomes prepared from soya PC, cholesterol and stearylamine in a molar ratio 
of 5:3:1. Nicolosi et al. (139) reported the successful encapsulation of vancomycin into 
liposomes consisting of dioleoyl phosphatidyl ethanolamine, dipalmitoyl phosphatidylcholine 
and cholesterol hemisuccinate in molar ratio of 4:2:4 using the REV method. The liposomal 
vancomycin exhibited an EE of 65%. 
1.5.1.1.3. Injection method 
The ethanol/ether injection method involves dissolving lipids in ethanol or ether, then slowly 
injecting this lipid solution through a fine needle into the aqueous phase, followed by 
evaporating the organic solvent. The injection results in the formation of unilamellar liposomes 
with a high EE (140). When comparing the ethanol injection with the ether injection method, the 
latter is more advantageous since residual ethanol might be a concern; in contrast to ethanol, 
ether is immiscible with aqueous solutions and can be removed upon heating the solvent under 
vacuum (133). Chorachoo et al. (141) prepared rhodomyrtone liposomal formulations that 
consisted of PC and cholesterol with ratio of 4:1 using the ethanol injection method. The 
encapsulation efficiencies of the liposomal formulations ranged between 51 and 65 %. The 
highest percentage of rhodomyrtone entrapment was in liposomes of 60 μmol/ml of total lipid 
concentration. The liposomal rhodomyrtone exhibited higher activity compared with the free 
formulation against Staphylococcus aureus. Another study investigated the encapsulation of 
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amphotericin B into three liposomal formulations prepared by the ethanol injection method and 
consisted of soya PC and cholesterol, dimyristoyl phosphatidylcholine and cholesterol, or 
hydrogenated soya PC and cholesterol in a molar ratio of 7:3 (142). The EE of amphotericin B 
ranged between 93 and 97 %. 
1.5.1.1.4. Detergent removal method 
The detergent is used to solubilize the lipids in a micellar solution (143). The detergent 
protects the hydrophobic part of lipids from interacting with the aqueous solution; consequently 
micelles are formed instead of liposomal vesicles. After drying the lipid mixture, an aqueous 
phase, that contains hydrophilic drugs, is added to prepare detergent-lipid micelles. Liposomes 
are spontaneously formed once the detergent is removed by dialysis, column chromatography or 
adsorption. One of the drawbacks of liposomes formed by this technique is the use of detergent 
removal procedures, which are time consuming and might result in removing other hydrophilic 
components (144). As well, only a few detergents are appropriate for use with this method such 
as alkylglycosides, sodium cholate and alkyloxypolyethylenes. Using this method, Daemen et al. 
(145) showed that 98 % of the doxorubicin was encapsulated within liposomal vesicles  
consisting of PC, cholesterol and phosphatidylserine in a molar ratio of 4:5:1.   
  1.5.1.2. Mechanical methods 
A mechanical force is applied to alter the size, lamellarity or homogeneity to produce a 
liposomal population with a specific size or property. The methods applied most often after 
liposome preparations are sonication and extrusion. These methods result in size, lamellarity and 
heterogeneity reduction (144). 
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1.5.1.2.1. Sonication 
Sonication is a simple method for liposome size reduction that can be achieved by exposing 
the MLVs to ultrasonic irradiation. Two sonication techniques can be used: i) probe sonication, 
and ii) bath sonication. The probe sonicator delivers high energy to the lipid, but has the 
disadvantage of degradation caused by overheating the lipid suspension (146). The probe 
sonicator also tends to release titanium particles that need to be removed from lipid suspension 
(147). The bath sonicator, however, enables one to control the energy that is delivered to the 
lipids, thereby preventing lipid overheating and enhancing the reduction of liposomal size (148, 
149). Bath sonication also is the most widely used technique for large volume preparations (136). 
Mugabe et al. (150) successfully prepared liposomal formulations that loaded different 
antibiotics including gentamicin, tobramycin, amikacin and erythromycin by the DRV method. 
After homogenization was performed via sonication, the resulting liposomal formulations had 
average sizes that ranged from 163 to 260 nm.  
1.5.1.2.2. Extrusion 
In this method, the size is reduced when the liposomes are forced to pass through 
polycarbonate filters with pore sizes of 1 µm under moderate pressures, followed by several 
cycles of extrusions through filters of decreasing pore size ranging from 0.6 to 0.1 µm at 
elevated temperatures (147). There are disadvantages with the extrusion method, including the 
long period of time required to reduce the size and the high product losses that may occur due to 
clogging of the extrusion membrane (151). Liposomal polymyxin B of defined size and 
homogeneity was prepared by sequential extrusion of multilamellar vesicles through a double-
stacked polycarbonate membrane. The resulting liposomes had a mean diameter of 172 nm 
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(152). Another study showed how extrusion also improved the homogeneity and reduced the size 
of liposome-loaded vancomycin (139). The average size of the liposomal vesicles was 103 nm. 
1.5.1.2.3. Microfluidization  
Microfluidization is a technique for reducing liposomal size, used in the pharmaceutical 
industry for large-scale production (153). The method is based on splitting a fluid stream into 
two parts and passing them through a fine orifice under high pressure (10,000 psi) to guide the 
flow inside the interaction chamber (154). The high pressure then directs the flow stream through 
microchannels toward the impingement area. Inside the interaction chamber, cavitation, along 
with shear and impact, reduces liposome size (153, 154). However, a disadvantage of the 
microfluidization method is the high pressure required to reduce the size, which may result in 
partial degradation of the lipids (155). As far as we know, this method has not been widely 
applied in preparing liposomes for treating infectious diseases. However, Boltic et al. (156) have 
reported the suitability of the microfluidization method to reduce the size of liposome-loaded 
antibiotics. The mean diameter of the liposomal vesicles after five homogenizing cycles was 380 
nm. 
1.5.2. Methods of characterization 
Liposomes prepared by any of the above-mentioned methods must be characterized. The most 
important characteristic parameters to be determined for optimizing stability and shelf life of 
liposomal formulations are particle size, lamellarity, zeta potential, and EE. 
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 1.5.2.1. Particle size 
Size and size distribution measurements of liposome formulations are important characteristic 
parameters that indicate the homogeneity of liposomes. Unchanged in the size and size 
distribution of liposomes can be used as indicators of long-term stability (154). 
Dynamic light scattering (DLS), electron microscopy and gel exclusion chromatography are 
widely used to measure the size of liposomes. The basic principle of DLS is a measurement of 
the diffusion coefficient as a result of Brownian motion. The diffusion coefficient is then used to 
calculate the size of the liposome (157). Transmission electron microscopy (TEM) at cryogenic 
temperature and freeze-fracture TEM are also used to determine polydispersity and size (158). 
However, light scattering and electron microscopy have their own advantages and drawbacks 
(154). For instance, light scattering provides the particle size of the entire sample, but it does not 
determine the morphology of liposomes. Additionally, this technique measures aggregation of 
two or more liposomal spheres as one vesicle which is larger than the actual size of a single 
liposomal sphere. Electron microscopy can determine the shape and actual size of particles; 
however, only a small population can be measured. A simple but powerful method is gel 
exclusion chromatography, in which an actual hydrodynamic radius can be detected. The main 
drawback of this method is the presence of positively-charged colloidal particles in columns tend 
to clog due to the possibility of electrostatic interactions with the medium which may have a 
negative charge (147). 
 1.5.2.2. Lamellarity 
The lamellarity of liposomes can be determined by measuring the phosphorus nuclear 
magnetic resonance (
31
P-NMR) signal of the phospholipid head groups of liposomes before and 
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after the addition of manganese ions (Mn
2+
) as a paramagnetic agent. The Mn
2+ 
interacts with the 
negative charge on phospholipids of the outer liposomal surface. The interaction results in 
broadening and reduction of the resonance signal. Direct comparison of the peak height of the 
two signals reveals the ratio of outer to inner phospholipid content (159). Although this method 
is commonly used, parameters including buffer and Mn
2+ 
concentrations as well as pH may 
affect the method’s accuracy (160). Microscopic techniques including scanning electron 
microscopy (SEM), confocal laser scanning microscopy (CLSM) and cryo-TEM are also used to 
determine the lamellarity (161). Not only do these show the accurate lamellarity, but they also 
give additional information such as shape and size. The size and lamellarity can be provided as 
well by small-angle X-ray scattering. 
 1.5.2.3. Zeta potential 
This potential indicates the overall charge present on the colloidal systems. The zeta potential 
measurement can also indicate stability of colloidal systems. Positive or negative surface charges 
on liposomes indicate higher stability due to surface repulsion between similarly-charged 
particles, hence inhibiting the aggregation of liposomes (162). Measuring the zeta potential is 
also important for monitoring the fusion and precipitation of liposomes, which relate to 
liposomal stability (154). 
 1.5.2.4. Encapsulation efficiency (EE) 
EE is usually defined as the percent fraction of entrapped drug to that of the initial 
concentration used in the liposomal preparation (150). EE is indicative of the quantity of drugs 
entrapped in liposomal formulations. EE can be used to optimize the formulation composition 
before studying the behavior of these entrapped agents in physical or biological systems. For 
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water-soluble drugs, encapsulation corresponds to the entrapment within the aqueous core. For 
lipophilic drugs, on the other hand, it implies entrapment within lipid bilayers. After removal of 
non-entrapped drugs from the aqueous phase, total lysis of liposome vesicles can be induced by 
addition of a detergent such as Triton X100 in an effort to measure EE. 
 High performance liquid chromatography (HPLC) is commonly used for determination of 
EE. Spectrophotometry, fluorescence spectroscopy, enzyme-based methods, microbiological 
assays and electrochemical techniques are also used for determining the EE depending on the 
nature of the entrapped materials (127, 154). 
1.5.2.3. Stability of liposomes 
In the pharmaceutical industry and in drug delivery, the capability of the product formulation 
to remain stable within a defined period of time is very important. The stability of liposomes is 
determined by a number of physical and chemical properties.  
The physical instability can be indicated by: 1) the increase of liposome size, 2) ratio between 
lipid and entrapped agent due to fusion, and 3) aggregation of membrane bilayers or leakage of 
encapsulated materials. Physical stability can be improved by storing the liposomes at low 
temperatures. Geusens et al. (163) studied the stability of cationic liposomes for 28 days at 4°C 
and 25°C; they found that the particle size was stable at 4°C but increased from 100 nm to 160 
nm at 25°C. 
Chemical instability can occur by hydrolysis or oxidation of lipids. Hydrolysis removes the 
hydrophobic chain of ester bonds, thereby leading to lipid destruction and leakage of 
encapsulated materials. Unsaturated lipids are more likely to be prone to oxidation from reactive 
oxygen species, thereby affecting liposomal fluidity (164). However, chemical and physical 
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stability of liposomes can be enhanced by lyophilization process which has been found to be 
suitable for long-term stability (165). 
 
1.6. Interaction of liposomes with cells 
Interest in liposomes is based on their biological membrane-like structure consisting of lipids 
organized in bilayer configuration. The device prevents its content from being released rapidly, 
and ensures that they are delivered to the desired target because of the liposomes’ ability to 
interact with host cells via lipid exchange, adsorption, endocytosis, or fusion (Diagram 10) 
 1.6.1 Lipid exchange 
Lipophilic materials can be transferred from liposomes to the cell membrane by lipid 
exchange. Lipid exchange is a method where liposomes exchange their own lipids for the lipids 
of diverse cell membranes (166). Although the exact mechanism is not fully understood, one 
possibility is the transfer of lipid monomers mediated by lipid exchange proteins existing at the 
cell surface. It is also possible that the outer monolayer of vesicles and the cell membrane 
undergo a reversible transient merger. Finally, an enzymatic exchange of acyl chains may take 
place  between  the liposomes and  plasma membrane lipids of the host cells (167). 
1.6.2. Adsorption 
Adsorption of liposomes to the cell membrane is another mechanism of liposome-cell 
interaction. Adsorption occurs without merging the liposomes with the cell membrane. 
Adsorption of liposomes into the cell membrane proceeds when attractive forces (e.g., long-
distance electrostatic interactions, van der Waals interactions, hydrophopic insertion and 
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hydrogen bonding) exceed the repulsive forces (e.g., short-distance electrostatic interactions, 
steric hindrance, hydration and protrusion) (168).  
  1.6.3. Endocytosis 
Cells with phagocytic activity engulf liposomes into endosomes. In turn, the endosomes fuse 
with the lysosomes resulting in the formation of phagosomes. Lysosomal enzymes digest the 
lipids in the phagosomes and convert them to fatty acids. The liposomes’ content is then released 
intracellularly  (169). 
  1.6.4. Fusion 
Fusion of biological membranes is a crucial process in the intracellular delivery of lipids. 
Close contact of liposomes leads to intermixing and diffusion of liposomal lipids with the lipids 
of the target plasma membrane, thereby allowing entrapped agents in the aqueous compartment 
to be injected directly into the cytoplasm (127). On the other hand, incorporated agents in the 
lipid bilayer are delivered into the bilayer membrane of the cell.  
 
 
Diagram 10: Schematic representation of possible mechanisms of liposome-cell 
interaction. (A) fusion, (B) adsorption, (C) lipid exchange and (D) endocytosis. 
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1.7. Routes of administration 
Encapsulated agents in liposomes might be introduced into a biological system by different 
anatomical routes. Delivering medication to a biological system may proceed via oral, 
intravenous or pulmonary routes. 
1.7.1. Oral administration 
This route is the preferred means of delivering medication due to the safety, ease of 
administration, and its widespread acceptance by patients. Oral administration of lipid based 
encapsulation systems has a direct impact on drug performance in vivo. Lipophilic drugs may 
dissolve in water very poorly, but in gastrointestinal fluids they are often solubilized by bile to a 
significant extent. Thus, orally-administered liposomes that have a large surface area enable 
pancreatic lipase to efficiently hydrolyze triglycerides, promoting solubilization of the lipophilic 
drug in the aqueous environment of the intestinal lumen (170). Gershkovich et al. (171) 
examined the pharmacokinetics of liposome-loaded amphotericin B administered orally and 
found that the oral liposome formulation has the potential for improving therapeutic treatment 
and prophylaxis of systemic fungal infections. 
1.7.2. Intravenous administration 
Intravenous administration is the infusion of water-soluble materials directly into a vein. As 
systemic circulation supplies blood to the whole organism, liposomes are transported from the 
site of injection directly to the heart via the venous network and then to organs. On 
administration of liposomes to systemic circulation, however, liposomes are cleared rather 
quickly from the blood by the mononuclear phagocytic system (MPS) (172). Thus, diverse 
strategies have been developed to extend the drugs’ half-life in circulation. For example, 
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incorporation of certain glycolipids such as phosphatidyl inositol in the bilayer resulted in 
shortened clearance time and reduced uptake by the MPS in the spleen and the liver (173, 174). 
Conjugating a stealth component such as polyethylene glycol (PEG) on the liposome’s surface 
resulted in prolonged circulation (175). The pharmacokinetics of intravenously-administered 
conventional liposome-loaded gentamicin showed that plasma half-life was prolonged compared 
with the free drug (176).  
1.7.3. Pulmonary drug delivery 
Liposome-encapsulated active agents can be delivered directly to the lung for local treatment 
of pulmonary diseases. This route offers greater access of active agents to the target site and 
allows for the use of effective but lower drug doses with reduced systemic toxicity. Liposomes 
seem to be a suitable and attractive option for therapeutic agent delivery to the lung, since they 
can be prepared from components compatible to the lung (177). Liposomal formulations have 
been delivered to the lung in the form of an aerosol, which can deliver the drug particles by 
inhalation either through nebulization as droplets or dry powder inhalation. 
 1.7.3.1 Nebulization 
Nebulization is a method of delivering active agents dissolved in liquid in the form of a fine 
mist inhaled into the lung by using spraying devices. These fall into two categories: ultrasonic 
and jet flow devices (178). Nebulization depends on whether we deal with a drug that is soluble 
in solution (e.g., water, saline or cyclosporine in alcohol) or an insoluble drug suspended in 
liquid (179).  
Ultrasonic devices have the advantage of delivering medication in a short time, but they are 
not widely applicable with macromolecules due to denaturation of recombinant human 
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deoxyribonuclease (e.g., dornase α) by overheating (180). Thus, ultrasonic devices are limited in 
their therapeutic use (181). Jet flow devices can be applied in order to deliver various types and 
volumes of drug solutions in higher concentrations. For example, Weers et al. (182) investigated 
the inhalation of liposome-loaded amikacin in terms of pulmonary deposition, clearance and 
safety. Inhalation of liposome-loaded amikacin was well tolerated up to 120 mg and resulted in 
the prolonged retention time when a commercial jet nebulizer was used. 
 1.7.3.2. Dry powder inhalation 
Dry powder inhalation is an alternative methodology for aerosolization and delivery of 
medication to the lung in the form of a dry powder. Dry powder inhalers (DPIs) are an 
alternative technique to pressurized metered dose inhalers (pMDI) for delivering active agents. 
DPIs provide the advantages of increased efficacy with simplified and shortened time of drug 
administration (179). 
A case in point is budesonide, a corticosteroid that inhibits inflammatory symptoms like 
edema seen in chronic obstructive pulmonary disease (COPD). Liposome-encapsulated 
budesonide for DPIs has been found to provide a sustained release for longer periods of time 
while reducing systemic toxicity (183). 
 
1.8. Biodistribution 
The use of liposomes in drug delivery can alter the biodistribution and the rate of clearance of 
the drug by causing it to adopt the pharmacokinetic parameters of the liposomes. After 
intravenous administration, liposomes are rapidly cleared from the systemic circulation since 
they are recognized as foreign bodies by the MPS of the reticuloendothelial system (RES), 
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particularly Kupffer cells in the liver and spleen (173, 174). The increased rate of mononuclear 
phagocyte uptake is due to opsonization by serum proteins such as albumin, lipoproteins, 
immunoglobulins and the complement C3a and C5a fragments (184). Numerous studies have 
focused on investigating the factors responsible for the regulation of this interaction. The uptake 
rate of mononuclear phagocyte is affected by liposome properties such as size, surface charge, 
membrane lipid packing, and fluidity.  
 The circulation kinetics of liposomes with a mean size of 120 nm was shown to exhibit a 
slower removal rate from the blood compared with those having a mean size of 230 and 360 nm, 
respectively (185). The use of charged lipids in liposomes has a direct effect on liposome 
pharmacokinetics as well. Previous studies have shown that the presence of negatively and 
positively-charged lipids in liposomes resulted in a high uptake rate of liposomes by the RES 
(186, 187). Furthermore, the interactions of liposomes with serum proteins, including 
apolipoprotein, are highly dependent on lipid composition. It is generally accepted that the effect 
of bilayer fluidity and manipulation of lipid composition can have an impact on liposome 
clearance from circulation. For instance, absence of cholesterol from liposomes resulted in 
bilayer destabilization by high-density lipoproteins (188), thus quickly eliminating liposome 
components from systemic circulation. Different strategies have been developed to overcome the 
rapid liposomal systemic clearance by coating the surface of liposomes with immobile 
molecules. The common characteristic of these inert molecules is the occurrence of a hydrophilic 
flexible chain that forms a periliposomal layer (e.g., glycolipid or poly amino acid). This 
periliposomal layer hinders the binding of blood plasma protein to liposomes, thereby inhibiting 
the interaction of the MPS with liposomes (189). Methods for extending liposome blood 
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circulation times are based on grafting them with: PEG, poly(hydroxyethyl-L-asparagine) 
(PHEA) and poly(hydroxyethyl-L-glutamine) (PHEG) (175, 185).   
 
1.9. Targeting of liposomes 
The delivery of liposomes to a specific site involves shuttling them to the target area while 
reducing their exposure to normal tissues. Liposomes have been employed for accomplishing the 
delivery of therapeutic agents to a selected site by two mechanisms, known as passive and active 
targeting. 
1.9.1. Passive targeting 
Passive targeting for liposome delivery uses the natural tendency of certain cells upon 
injection into the circulatory system. For example, liposomes can be taken up by the RES in a 
passive manner. This uptake can be very useful in targeting diseases associated with parasites 
living inside macrophages such as leishmaniasis, candidiasis, and listeria. Once the liposomes 
are engulfed by the macrophages, the macrophages will degrade the liposomes resulting in the 
release of encapsulated drug within the macrophage (190). Therefore, the drug will reach the 
target site directly. Similarly, liposomes with a relatively small diameter can extravasate and 
accumulate in tissues characterized by leaky vasculature, such as solid tumors (191). This 
accumulation, which occurs due to retention of liposomes at sites of enhanced vascular 
permeability, will result in the creation of a high local drug concentration (192). 
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1.9.2. Active targeting 
Active targeting of liposomes involves controlling and directing the movement of liposomal 
vesicles with specific ligands coupled into the liposomal structure to target-specific tissues or 
cells. These so-called immunoliposomes improve the therapeutic availability of encapsulated 
drugs and minimize the adverse effects to non-target cells within pathological tissues. Examples 
of active targeting liposomal structure include concanavalin A-modified liposomes, mannose-
modified liposomes, monoclonal antibody (mAb)-modified liposomes, folate-modified 
liposomes, and transferrin-modified liposomes. 
 1.9.2.1. (Concanavalin A)-modified liposomes 
Lectins are glycoproteins or protein receptors that recognize sugar molecules, what makes 
them capable of binding to glycosylated molecules on cell membranes (193). The immobilization 
of carbohydrate ligands onto liposomal surfaces have led to the development of targeted 
liposomal delivery systems based on a carbohydrate–lectin interaction (194). Sudheesh et al. 
(195) reported that a concanavalin A-anchored liposomal amphotericin B exhibited higher 
activity on inhibiting the Candida albicans growth within a biofilm community, compared with 
conventional liposomes loaded with amphotericin B. 
1.9.2.2. Mannose-modified liposomes 
Another approach to target liposomes in infectious diseases consists of grafting mannose, 
instead of lectin, on liposomal surfaces. Mannose has the ability to recognize mannose receptors 
including mannose-binding lectins, which are highly expressed in cells of the immune system 
such as macrophages and dendritic cells (196). In addition, mannose binding proteins are capable 
of binding to a wide variety of cellular components including lipopolysaccharides, 
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lipoarabinomannan and lipophosphoglycan (197). Chono et al. (198) reported a higher efficacy 
for mannosylated liposomal ciprofloxacin against bacteria compared with unmodified liposomal 
ciprofloxacin in vitro. Same study showed that targeting ciprofloxacin to alveolar macrophages 
in a rat model of pulmonary infection was significantly higher in mannosylated liposomal 
ciprofloxacin than conventional liposome-loaded ciprofloxacin. 
1.9.2.3. (Monoclonal antibody)-modified liposomes 
Antibodies are frequently used as ligands because they can be applied against a variety of 
antigens and often exhibit high affinity and selectivity for their antigen. A tumor-specific mAb 
2C5 is capable of recognizing a wide variety of tumor cells. This antibody was used to modify 
the surface of liposome loaded meso-tetraphenylporphine (TPP) for tumor photo-dynamic 
therapy in vivo. The modification of liposome-entrapped TPP by mAb 2C5 resulted in enhancing 
the efficacy of TPP and increasing the accumulation of the drug in tumor cells (121). However, it 
has been reported that using whole antibodies may trigger complement-mediated cytotoxicity 
and antibody-dependent cellular toxicity (199). To prevent these effects, Fab fragment (a region 
on the antibody that binds to antigens) can be used instead of using the whole antibody. 
Modifying liposomes with antibody fragments resulted in prolonging the circulation time and 
enhancing the accumulation of liposomes in solid tumors (200). 
 1.9.2.4. Folate-modified liposomes 
Since folate receptors are often overexpressed in tumor cells, targeting these cells with folate-
modified liposomes has been successfully applied (201). Indeed, intravenously administered 
folate-targeted liposome-loaded doxorubicin in mice bearing KB tumors was investigated (202). 
Surface modification of liposome-loaded doxorubicin with folate increased the accumulation of 
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drug in tumor tissues and antitumor efficacy of the doxorubicin while prolonging the circulation 
time. 
 1.9.2.5. Transferrin-modified liposomes 
In addition to antibody- and folate-targeting liposomes for tumor cells, modifying the 
liposomal surface with transferrin has also attracted attention. Transferrin receptors are 
overexpressed on the surface of a variety of tumor cells and can be internalized after binding of 
transferrin to cell receptors (203). Therefore, the coupling of transferrin into the liposome 
structure offers longevity and the ability for drug delivery into the tumor. Transferrin-PEG-
liposome-loaded oxaliplatin injected intravenously into colon tumor-bearing mice was 
investigated and found that surface modification of liposomal formulations exhibited a long 
circulation time, low uptake rate by the RES in vivo, an enhanced accumulation in tumor cells for 
over 72 h after administration and suppressed tumor growth (204).  
 
1.10. Toxicity of liposomes 
Liposomes are usually considered as biocompatible, biodegradable, and relatively non-toxic 
because they are composed of lipids from natural sources that reduce the toxicity of entrapped 
bioactive agents. Previous studies showed that liposomes prepared from naturally occurring 
compounds are not toxic to culture cells in vitro (205, 206). However, when toxicity is associated 
with empty liposomes, it has not resulted from the lipids; rather, toxicity is coupled with the 
liposomal net charge and presence of volatile organic solvents (154, 206). 
A previous study has reported that charged liposomes show highly cytotoxic effects whereas 
neutral liposomes are not toxic (206). Preparation of liposomes using positively charged lipids 
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exhibited a highly toxic effect to epithelial lung cells, whereas negatively charged liposomes 
were relatively not toxic (206). Another study investigated the effect of charged liposomes on the 
buccal cells and found that positively charged liposomes were toxic; in contrast, negatively 
charged liposomes exhibited relatively low toxicity (207). The cytotoxicity of charged liposomes 
has not been completely elucidated. However, it has been proposed that the cytotoxicity results 
from the intermixing of cationic lipids in liposomes with the anionic lipids of cell organelles 
such as cardiolipin in the mitochondrial membrane (208). Another study investigated cationic 
liposome toxicity in the lungs and showed that positively charged liposomes can induce the 
production of toxic reactive oxygen intermediates (209). Although cationic liposomes are toxic, 
they play an important role as vaccine delivery systems (210). The majority of liposomal 
preparation methods require the use of organic solvents or detergents to solubilize the lipids. 
Residues of these solvents might not be removed completely from the final liposome solution, 
thereby causing a high potential for cytotoxicity via a number of suggested mechanisms. These 
mechanisms could include enzyme inhibition, protein denaturation, and cell membrane 
modification as well as extraction of outer cellular components such as lipids, cholesterol and 
proteins (211-213). Classical approaches can be applied to ensure solvent removal such as 
dialysis, evaporation under vacuum and gel filtration in an effort to reduce the cytotoxicity of 
liposomal formulations. 
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1.11. Application of liposomes 
1.11.1. In vitro studies 
Although polymyxin B can control a variety of bacterial infections including those by P. 
aeruginosa, its toxic side effects, including ototoxicity, nephrotoxicity and neuromuscular 
blockade are barriers to its use (214). However, it has been shown that the application of 
liposomal formulations could attenuate the side effects of drugs (215). Furthermore, in vitro 
studies on Bordetella bronchiseptica, P. aeruginosa, Escherichia coli, Klebsiella pneumonia, 
Acinetobacter lwoffii and Acinetobacter baumannii strains showed that encapsulation of 
polymyxin B in liposomes improved antimicrobial activity and reduced bacterial population in 
the presence of polyanions and sputum. This can illustrate the general observation that liposomes 
protect polycationic antibiotics from inactivation by polyanionic components present in sputum 
(129, 152).  
Liposomal formulations consisting of dicetyl phosphate (DCP) or dimyristoyl phosphatidyl 
glycerol (DMPG) loaded with vancomycin were evaluated in vitro against methicillin-resistant 
Staphylococcus aureus (MRSA) (216). Both liposomal formulations showed an improvement in 
the antimicrobial activity of vancomycin. Minimum inhibitory concentrations (MIC) of the 
liposomal formulations against MRSA strains were two- to fourfold lower than that of free 
vancomycin. Likewise, the minimum bactericidal concentrations (MBC) of both liposomal 
vancomycin formulations were fourfold less as well. Incorporation of vancomycin or 
ciprofloxacin in cationic, anionic and neutral liposomes improved the efficacy of encapsulated 
drugs against S. aureus. Cationic liposome, however, showed more potent activity than neutral 
and anionic formulations (217). Another study demonstrated that a cationic liposome-loaded 
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ciprofloxacin showed two to four times higher antibacterial activity compared with free drug 
against Gram-negative bacteria including P. aeruginosa, E. coli and K. pneumoniae (135). The 
enhanced activity of cationic formulation might be explained by the interaction of the negatively 
charged bacterial cell membrane with the positively-charged liposome surface (218). This 
interaction led to increased accumulation of encapsulated drugs in the periplasm, allowing a 
large number of antimicrobial molecules to diffuse in the cytoplasm (135).             
Aminoglycosides, including amikacin, netilmicin and tobramycin, loaded into cationic 
liposomes composed of lecithin, stearylamine and cholesterol or anionic liposomes consisting of 
lecithin, DCP and cholesterol, were investigated in vitro (125). Although the liposomal 
formulations exhibited a consistent release profile in human pooled sera; however, there was no 
significant difference in antibacterial activity between encapsulated and free drugs. Absence of 
enhanced activity of liposomes-encapsulated amikacin, netilmicin and tobramycin was explained 
in another study by the slow release of the drugs from liposomes, which prevented a sufficient 
amount of antibiotic to act directly on bacteria (219). However, other studies reported that 
liposomal aminoglycosides fuse with the outer membrane of P. aeruginosa and Burkholderia 
cenocepacia leading to the delivery of a high dosage of aminoglycosides into bacterial cells as 
confirmed by TEM, immunocytochemistry, lipid mixing assays and flow cytometry (127, 134). 
In other words, liposomes suppress the drug resistance of infectious organisms by offering a 
protection for antimicrobial agents from being effluxed (214).  
Encapsulation of amikacin, tobramycin and gentamicin in liposomes consisting of dipalmitoyl 
glycerophosphocholine (DPPC) and cholesterol (in a molar ratio of 2:1) exhibited more potent 
anti-pseudomonal activity than the free drug (127). The liposome-encapsulated aminoglycoside 
formulations also improved killing time and prolonged antimicrobial activity. Furthermore, a 64-
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fold reduction of the MIC with amikacin (512 mg/l for free drug vs 8 mg/l for liposomal 
amikacin), a 128-fold reduction with tobramycin (1,024 mg/l for free tobramycin vs 8 mg/l for 
liposomal tobramycin) and a 16-fold reduction with gentamicin (256 mg/l for free drug vs 8 mg/l 
for liposomes) were observed (127). Similar results for liposome-loaded gentamicin in the MIC 
reduction were noted for liposomes consisting of dimyristoyl glycerol phosphocholine (DMPC) 
and cholesterol (in a molar ratio of 2:1) (220). Furthermore, co-encapsulation of bismuth-
ethanedithiol (BiEDT) with tobramycin in liposomes showed a synergistic effect against P. 
aeruginosa, by enhancing its penetration into sputum and inhibiting bacterial growth within the 
biofilm structure. Moreover, the formulation reduced toxic side effects of BiEDT on lung 
epithelial cells as indicated by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and lactate dehydrogenase (LDH) assays (123, 128). We reported that liposomal BiEDT-
encapsulated tobramycin reduces P. aeruginosa quorum sensing signaling molecules, as well as 
production of lipase, chitinase, and protease in vitro, via a fusion mechanism (120).  
The efficacy of liposomal formulations of different surface-charged encapsulated 
clarithromycin was investigated against P. aeruginosa clinical isolates from CF patients. 
Liposomal formulations improved the MIC and MBC against clinical isolates compared with 
free formulation. Although using neutral liposomes were more effective than free formulations in 
reducing bacterial growth, positively and negatively-charged liposomes showed more 
elimination of the bacterial growth within the biofilm and were more effective in reducing 
virulence factors and bacterial motility (206).     
 Liposomal meropenem was also tested against sensitive and resistant strains of P. aeruginosa 
in vitro and showed an improvement in bactericidal activity of the encapsulated drug as the MIC 
results were two to four-times lower than the MICs of free meropenem for sensitive strains 
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(221). Benzyl penicillin-loaded liposomes inhibited the growth of a penicillin-sensitive strain of 
S. aureus at lower concentration and shorter exposure time than the free drug (222). 
Application of liposomes is an effective therapeutic delivery system in fungal infections. 
Polyene antibiotics such as amphotericin B, are utilized in the treatment of candidiasis and 
aspergillosis systemic infections. The mechanism of action of amphotericin B involves binding 
to ergosterol, a major sterol molecule in fungal membranes, resulting in changes to membrane 
permeability leading to metabolic disruption, osmotic imbalance, and as a consequence, cell 
death (223). The conventional amphotericin B with deoxycholate as a surfactant is associated 
with significant toxicities including infusion-related reactions, nephrotoxicity, and hypokalemia 
(224). However, liposome-loaded amphotericin B appears to have less nephrotoxicity than the 
conventional formulation and amphotericin B lipid complex (225, 226). 
1.11.2. In vivo studies 
Liposomes can alter the distribution of the encapsulated drug molecules in the body, which 
might extremely improve the efficacy of the treatment. Much interest has been focused on the 
application of liposomes as drug carriers using in vivo studies for treatment of several bacterial 
and parasitic infections (120, 214, 216, 227). 
Encapsulation of aminoglycoside antibiotics have been shown to have a superior effect on 
treating bacterial infections. A previous study showed that encapsulation of amikacin into 
liposomes administered intravenously in Mycobacterium avium mice infection model resulted in 
an increase of drug concentration in liver and spleen for up to 28 days (228). Furthermore, a once 
monthly of liposomal formulation treatments increased the survival time of infected mice up to 7 
months, compared with 4 months in the control group. Although liposomal amikacin reduced the 
bacteria load in the lungs (compared with the control) after a single injection of liposomal 
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formulation in a month, it did not eliminate bacterial growth due to low drug concentration 
measured in the lungs.  
A previous study showed that labeled liposomes administered intravenously in mice were 
found in high concentration in the liver and spleen, whereas lower amounts of liposomes reached 
the lungs (119). However, the bactericidal effect of long circulating liposomal amikacin given 
intravenously to mice showed two to six times higher antibacterial activity in the lungs compared 
with free drug (229). Liposomal amikacin showed two to six times higher antibacterial activity in 
spleen and lungs compared with free drug or combination of free amikacin and streptomycin 
when they were administered three-times a week. Administration of long circulating sterically 
stabilized liposomal amikacin to mice infected with M. avium showed an elimination of bacteria 
from infected organs, a decreased treatment period, and prevented relapse of bacterial infection 
(230). A similar finding is reported with the use of liposomal amikacin in a chronic P. 
aeruginosa lung infection in rats (231). This formulation also resulted in prolonged amikacin 
residence time in the airway thus allowing longer dosing intervals. Liposomal amikacin loaded 
into a PARI LC STAR nebulizer was investigated in a healthy male volunteer (182). The study 
demonstrated that a high percentage (70% of total liposomal formulation delivered to the body) 
was deposited in the lung and cleared slowly. The treatment was well tolerated with no 
significant clinical changes, including vital signs and lung function parameters. A randomized 
placebo-controlled Phase II study conducted in Europe demonstrated that administration of 
liposomal-loaded amikacin at 280 and 560 mg once-daily for 28 days improved force expiratory 
volume in 1 second (FEV1) versus placebo (232). The liposomal amikacin exhibited a prolong 
release of the antibiotic with no observed toxicity. A continuous open-label study of liposomal 
amikacin administered at 560 mg once-daily for 6 cycles, each cycle consisting of 28 days on, 
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followed by 56 days off treatment, showed a sustained improvement in lung function (233). 
There was also a significant reduction in non-mucoid and mucoid strains of P. aeruginosa cell 
counts, even during the 56 days off treatment. There was no significant change in the MICs over 
the study and Phase III trial was initiated. 
Results of investigations into the pharmacokinetic and the bactericidal effect of liposomal 
tobramycin are promising as well. Intratracheal administration of liposomal tobramycin in 
animal models of chronic pulmonary infection caused by mucoid P. aeruginosa improved the 
pharmacokinetic of tobramycin and was more effective in eliminating the bacteria (132, 234). 
We reported a significant improvement in efficacy of co-encapsulated BiEDT and tobramycin 
administered intratracheally in rats with chronic pulmonary infection caused by a resistant 
clinical strain of P. aeruginosa (120). In addition to improving bactericidal activity, the 
liposomal formulation showed a sustained concentration of tobramycin at the infection site, a 
reduced nephrotoxicity, minimal systemic absorption and a modulation of IL-8 levels in the 
lungs and sera. 
CpG oligodeoxynucleotide (CpG ODN) is a synthetic immunomodulator that increases nitric 
oxide production by macrophages in vivo (235). Encapsulated CpG ODN in cationic liposomes 
consisting of DOTAP exhibited the highest protective effect compared with the free form against 
Burkholderia pseudomallei in mice (236). The intracellular bacterial counts in mice macrophages 
treated with CpG ODN-DOTAP were reduced by 92% compared to the control, whereas the 
group treated with CpG ODN alone exhibited a 45% reduction in intracellular bacterial counts. 
The reduction in levels of intracellular bacteria resulted from increased production of nitric oxide 
by macrophages. In addition, the liposomes were able to localize in the liver and spleen, where 
45 
 
many infectious organisms reside, rendering liposomes useful for targeting antibiotics to these 
organs. 
 Efficacy of liposomal formulations against challenging intracellular mycobacterial infections 
has also been tested. Encapsulation of rifabutin (RFB) in liposomes exhibited an improvement in 
bactericidal activity more than free RFB against M. avium (237). Likewise, liposomal 
formulation administered intravenously in Mycobacterium tuberculosis infected mice decreased 
injuries in the liver, spleen and particularly in the lungs. The liposomal formulation also reduced 
M. tuberculosis in the lung significantly compared with free drug. This study concluded that 
liposomes with high transition temperature were more efficient in enhancing the delivery of 
RFB. Administration of the drug delivered by lung-specific liposomes of RFB enhanced RFB’s 
anti-tuberculosis effects in mice and significantly reduced its hepatotoxicity (238). When RFB-
loaded tuftsin-bearing liposomes were delivered twice weekly for 2 weeks, the load of lung 
bacilli was effectively lowered at least 2,000 times more than treatment with the free drug in vivo 
(239). 
MRSA is one of the challenging infections that worry public health (240). Conventional 
liposomal vancomycin administered intraperitoneally reduced bacterial infection in murine 
systemic infection caused by MRSA in kidney and spleen by 100 to 1000 times compared with 
the control (216). Various pieces of evidence supported the idea that the improved efficacy of 
liposomal formulation might be due to fusion of liposomes to the bacterial cell wall (127). 
Other research has focused on PEGylated surface-modified liposomes-loaded vancomycin 
over conventional liposomes in treating MRSA infections of the lungs in murine (241). The 
liposomal formulations showed a sustained vancomycin concentration in plasma for the 48 days 
of the study, whereas free vancomycin concentration was not detected after 2 h of injection. In 
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addition, both liposomal formulations significantly improved the biodistribution of vancomycin 
compared with free agent in liver and spleen; however, surface modification of liposomes 
significantly increased deposition of vancomycin in the lung compared with conventional 
liposomes. It is believed that surface modification of the liposomes protected the liposomes from 
being cleared rapidly by liver and spleen and prolonged the circulation time; therefore, it might 
be an efficacious treatment approach against MRSA in pneumonia.  
The persistence of infection in osteomyelitis due to contamination of bone tissues can be 
attributed to the rapid removal of antibiotics by the RES of Kupffer cells of the liver, bone 
marrow and macrophages of the spleen. Liposomal antibiotics may improve efficacy of 
antimicrobial drugs in treating infections in hard tissues. Intravenous administration of cationic 
liposomes-encapsulated vancomycin or ciprofloxacin was more effective in reducing infection in 
rabbit bone caused by S. aureus (217). Administration of liposomal formulations for 7 - 14 days 
resulted in 1.5- or 2- fold reduction in severity of the disease, respectively. The latter time point 
cured infections in 30% - 50% of the animal population. The combination therapy of liposomal 
ciprofloxacin and liposomal vancomycin for 14 days, however, cured all infected rabbits with 
reduced nephrotoxicity. The successful therapy of combining vancomycin and ciprofloxacin in 
liposomal form might be explained by the ability of liposomes to prolong circulation time of 
encapsulated drugs and avoid the uptake by macrophages. 
A previous study investigated the pharmacokinetic, the biodistribution and the efficacy of 
single doses of liposomal ciprofloxacin administered intravenously at concentrations ranging 
between 0.2 and 8 mg/kg in murine model of systemic Salmonella dublin infection (242). 
Liposomal formulation increased mice survival compared with free ciprofloxacin; a single dose 
of liposomal ciprofloxacin at 1/16 of the highest concentration resulted in survival 60% of 
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infected mice, whereas free drug at same concentration did not prevent mortality. Administration 
of a single dose of liposomal formulation at 1/4 of the highest concentration increased murine 
survival up to 83%, whereas administration of free agent at same concentration for 5 days 
exhibited 33% murine survival. The liposomal formulation exhibited a sustained drug release 
and prolonged the persistence of agents for 48 h in liver and spleen, whereas there was no 
ciprofloxacin detected in liver and spleen at 8 h. The study also showed that liposomal 
formulation was more effective in reducing bacteria community in liver, spleen, lymph nodes, 
Peyer’s patches and stool. The effectiveness of liposomal ciprofloxacin was dose dependent. 
Chono et al. (243) investigated the pharmacokinetics and pharmacodynamics of pulmonary-
administered liposomal ciprofloxacin in rats with lipopolysaccharides-induced pneumonia. 
Administration of liposomal ciprofloxacin enhanced the distribution of antimicrobial agents in 
epithelial lining fluid in the lungs compared with free agent and resulted in a sustained release of 
encapsulated agent throughout the study. Furthermore, the liposomal formulation increased the 
delivery of ciprofloxacin to alveolar macrophages and reduced systemic toxicity. 
Pharmacokinetic and pharmacodynamics parameters showed a markedly increased efficacy for 
liposomal formulation, suggesting that liposomal ciprofloxacin formulation could be a useful 
treatment to target intracellular and extracellular infection associated with pneumonia.  
The infected macrophages have been shown to overexpress mannose receptors that bind 
and internalize mannose-terminated glycoproteins (244). These receptors can effectively be 
targeted with appropriate delivery systems. Mannose-grafted liposomes with entrapped 
amphotericin B are more effective in reducing Leishmania donovani than free and unmodified 
liposome-entrapped amphotericin B. The improved reductive effect can be attributed to enhanced 
uptake of mannose-coupled liposomes by the mannosyl-fucosyl receptor present on the 
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macrophage surface. Thus, macrophage-rich organs such as the liver and spleen exhibited an 
increased accumulation of the drug for prolonged periods of time in L. donovani-infected golden 
hamsters (245). Chagas disease caused by Trypanosoma cruzi leading to cardiac failure is one of 
the worst parasitic diseases in terms of mortality and morbidity. Liposome-encapsulated 
amphotericin B was investigated in mice infected with T. cruzi and found to reduce infections in 
heart, liver, spleen, skeletal muscle and adipose tissues. Administration of liposomes-loaded 
amphotericin B in early stages of infection resulted in reduced T. cruzi loads in the spleen and 
liver, allowing the survival of the infected animals (246). A randomized comparative study 
evaluated the safety and efficacy of intravenously-administered liposomal amphotericin B 
compared with free formulation in treatment of febrile neutropenia patients (247). Although 
there was no statistically significant difference in duration of treatment, time to resolve fever and 
absolute neutrophil count between treatment groups, adverse effects of treatment such as 
vomiting, nausea, fever and headache were higher with conventional amphotericin B compared 
with the liposomal formulation. Furthermore, administration of liposomal formulation at 1 
mg/kg/day was equally efficacious and well-tolerated at 3 mg/kg/day. 
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1.12 Thesis objective 
The aim of this research thesis was to investigate the efficacy of co-encapsulation of 
bismuth-ethanedithiol and tobramycin into liposomal vesicles at sub-inhibitory concentration 
against P. aeruginosa to reduce quorum sensing signaling molecules and virulence factors, in 
vitro. In addition, the bactericidal efficacy of this liposomal formulation in an animal model of 
chronic pulmonary infection with P. aeruginosa was investigated. 
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Abstract 
We sought to investigate alterations in the quorum-sensing signal molecule, N-acyl 
homoserine lactone, secretion and in the release of Pseudomonas aeruginosa virulence factors as 
well as in vivo antimicrobial activity of bismuth-ethanedithiol incorporated into a liposome-
loaded tobramycin formulation (LipoBiEDT-TOB) administered to rats chronically infected with 
P. aeruginosa. The quorum-sensing signal molecule, N-acyl homoserine lactone, was monitored 
by using a biosensor organism. P. aeruginosa virulence factors were assessed 
spectrophotometrically. An agar beads model of chronic Pseudomonas lung infection in rats was 
used to evaluate the efficacy of the liposomal formulation in the reduction of bacterial count. The 
levels of active tobramycin in the lungs and the kidneys were evaluated by microbiological 
assay. LipoBiEDT-TOB was effective in disrupting both quorum-sensing signal molecules, N-3-
oxo-dodecanoylhomoserine lactone and N-butanoylhomoserine lactone, as well as significantly 
(P<0.05) reducing lipase, chitinase and protease production. At 24 h, after 3 treatments, the CFU 
counts in lungs treated with LipoBiEDT-TOB were of 3 log10 CFU/lungs comparatively to 7.4 
and 4.7 log10 CFU/lungs, in untreated and in lungs treated with free antibiotic, respectively. The 
antibiotic concentration after the last dose of LipoBiEDT-TOB was 25.1 µg/lung, while no 
tobramycin was detected in the kidneys. As for the free antibiotic, we found 6.5 µg/kidneys, but 
could not detect any tobramycin in the lungs. Taken together, LipoBiEDT-TOB reduced the 
production of quorum sensing molecules and virulence factors and could highly improve the 
management of chronic pulmonary infection in cystic fibrosis patients. 
 
Keywords: cystic fibrosis, aminoglycoside, cytokines, virulence factors, quorum sensing. 
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2.1. Introduction 
Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutation in a cystic 
fibrosis transmembrane regulator (CFTR) gene that affects organs and systems including the 
lungs, the pancreas, the endocrine system and the gastrointestinal tract (1). Pulmonary injury is 
the most challenging medical problem and is responsible for the majority of morbidity and 
mortality in the CF population (2). There are more than 1500 mutations in CFTR genes with 
different degrees of disease severity. The mutation in CFTR gene caused by deletion of 
phenylalanine at position 508, known as ΔF508, is more common and causes severe disease due 
to non-functional chloride ion channels (3). Normal lung epithelial cells keep the epithelial lining 
fluid of the airways hydrated to ensure appropriate mucociliary clearance of allergens or 
microbes from the airways (4). Hydration of the mucosal surface of epithelial cells is linked 
osmotically to sodium transport and chloride secretion. The mutations in CFTR lead to 
dysfunctional or compromised chloride ion channels as well as hyper-absorption of sodium 
through sodium channels (ENaC). The resultant thick sticky mucous (5, 6) provides a suitable 
growth environment for bacteria such as Staphylococcus aureus, Haemophilus influenzae, 
Pseudomonas aeruginosa, and Burkholderia cepacia (7-9). Recurrent P. aeruginosa- induced 
pulmonary infection and inflammation is more common and is associated with reduced lung 
function and disease exacerbation (10, 11). 
P. aeruginosa is a Gram-negative opportunist human pathogen found in various environments 
such as fresh water, plants, sinks, hand soaps, and hospitals (12, 13). P. aeruginosa cells interact 
with specific host cell receptors through appendices such as type IV pili, which recognize the 
over-expressed asialoganglioside (GM1) in CF epithelial cells; and its monotrichous flagellum 
binds specifically to secreted respiratory mucins (14-16). P. aeruginosa utilizes mucus as a 
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shield against the host immune system and regulates its cell density, virulence factor production, 
and biofilm formation through quorum sensing (QS) signaling (17-20). The pathogen carries two 
homologues that control the QS system: the lasI/lasR and rhlI/rhlR (21). The autoinducer 
proteins are responsible for synthesizing specific signal molecules. LasI and RhlI synthesize N-3-
oxo-dodecanoylhomoserine lactone (3O-C12-HSL) and N-butanoylhomoserine lactone (C4-HSL), 
respectively; whereas, LasR and RhlR function as transcriptional activator proteins (22-24). 
Bacteria release 3O-C12-HSL at certain cell density into the external environment, where it binds 
to LasR forming a complex that binds promoters to induce a wide variety of virulence factors, 
including lipase, chitinase, and proteases (25-29). Activation of airway epithelial cells signaling 
pathways, in response to P. aeruginosa pulmonary infection, results in gene expression and 
secretion of several cytokines and chemokines including IL-8, a potent chemoattractant of 
neutrophil (30). While neutrophils eradicate bacteria, their toxic products, such as elastase and 
reactive oxygen radicals, in the airway, damage the lung tissue as well (31).  
Aggressive chemotherapy, through various routes, has been utilized to decrease the 
persistence of P. aeruginosa in lungs (32, 33). Administration of aminoglycosides such as 
tobramycin, along with β-lactams, is usually prescribed against P. aeruginosa to reduce infection 
(34, 35). Tobramycin at sub-inhibitory concentration reduces production of P. aeruginosa 
virulence factors at translation level by inhibiting the release of C4-HSL and 3O-C12-HSL levels 
(36, 37). However, since a high dosage and prolonged use of tobramycin are required to 
eradicate bacteria, a high risk of ototoxicity and nephrotoxicity exists (34). Furthermore, the 
presence of mucus, overexpression of multidrug efflux pumps, and bacterial transition to biofilm 
form result in a poor prognosis (38-41). 
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 Bismuth subsalicylate and bismuth subcitrate have been used for years to treat 
gastrointestinal disorders associated with Helicobacter pylori (42). A combination of bismuth 
and thiol agents increases the bismuth solubility, lipophilicity, and its anti-microbial activity 
against Gram-positive and Gram-negative bacteria (43). Huang and Stewart have shown that 
bismuth dimercaprol was able to reduce biofilm formation by P. aeruginosa (44). Bismuth- 
ethanedithiol (BiEDT) along with tobramycin have a synergistic effect against P. aeruginosa and 
Burkholderia cepacia in vitro (45, 46). The cytotoxic effects of bismuth, however, limit its 
utility. BiEDT, at concentrations of 10 and 20 µM, render human lung cells in culture nonviable 
(47). Microcarriers such as liposomes are used to overcome toxicities of the drugs, to sustain the 
release of drugs at the target site, and to prolong their residence time (48, 49). 
 
Liposomes are small lipid vesicles with a size ranging from nanometers to micrometers. They 
are generally a safe delivery system since liposomes are biocompatible and biodegradable. They 
consist of phospholipid bilayers with an aqueous core. Hydrophilic drugs can be encapsulated in 
the aqueous core, whereas lipophilic drugs can be incorporated into the bilayers. Recently, more 
research has focused on utilizing liposomes to deliver therapeutic molecules to target sites 
including the lungs (50). Liposomes are preferred for antibiotic delivery because they provide a 
sustained release of the drugs and reduce side effects, as well as increasing the bioavailability of 
insoluble hydrophopic drugs (50, 51). Previous studies in our laboratory have shown that 
coencapsulation of BiEDT with tobramycin in liposomes resulted in elimination of the BiEDT 
toxic effect on human lung cells while increasing its antibacterial efficacies against P. 
aeruginosa and B. cepacia (52, 53). 
The current study was performed to test whether liposomal BiEDT loaded tobramycin 
(LipoBiEDT-TOB) at sub-inhibitory concentrations is able to reduce production of virulence 
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factors and QS signal molecules by P. aeruginosa in vitro and to enhance the antimicrobial 
efficacy as well as to examine anti-inflammatory effect of LipoBiEDT-TOB on the animal model 
of chronic pulmonary infection with the aforementioned bacteria. 
2.2. Materials and methods 
2.2.1. Chemicals and media 
1, 2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) was purchased from Northern Lipids, 
(Vancouver, BC, Canada). Cholesterol, bismuth nitrate [Bi (NO3)3·5H2O], 1, 2-ethanedithiol 
(EDT), propylene glycol (PG), heavy mineral oil, xylazine, saline, chitin azure, β-D-
galacopyranoside and Triton X-100 were obtained from Sigma–Aldrich (Oakville, ON, Canada). 
Sodium hydroxide (NaOH), sodium deoxycholic acid (C24H39O4Na), tobramycin, chloroform 
and methanol were purchased from Fisher Scientific (Ottawa, ON, Canada). Tryptic soy agar, 
Tryptic soy broth, Luria-Bertani (LB) broth, Luria-Bertani agar and Mueller-Hinton agar were 
purchased from Becton Dickinson Microbiology Systems (Oakville, ON, Canada). Ketamine 
was obtained from Animal Health Inc.(Cambridge, ON, Canada). 
2.2.2. Bacterial strains 
PA-489122 strains of P. aeruginosa were used throughout the experiment and had been 
isolated from CF patients at Sudbury Regional Hospital (Sudbury, Ontario, Canada).  
Staphylococcus aureus ATCC 29213 was used as an indicator of tobramycin activity, as 
recommended by the Clinical and Laboratory Standards Institute (CLSI). All strains were stored 
in Mueller-Hinton  broth at -80°C supplemented with 10% glycerol. All strains were grown for 
18 h in ABt medium (27 mM (NH4)2SO4, 30 mM Na2HPO4·2H2O, 20 mM KH2PO4, 47 mM 
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NaCl, 1 mM MgCl2, 0.1 mM CaCl2, 0.01 mM FeCl2, 0.5% w/v glucose, 0.5% w/v casamino 
acids and 0.00025% w/v of thiamine) broth prior to the MIC, QS, and virulence factors 
experiments. Agrobacterium tumefaciens strain A136 (pCF218)(pCF372) (Ti
-
)  was used as the 
biosensor for the detection of AHL and cultured in Luria-Bertani (LB) broth at 30°C. 
2.2.3. LipoBiEDT-TOB preparation 
A dehydration-rehydration method was used to prepare liposomal bismuth tobramycin. To 
prepare BiEDT, Bi (NO3)3 and 600 mM of NaOH were dissolved first in 25 mL of methanol. 
One mL of EDT was then added to the mixture. To prepare the liposome vesicles, DSPC and 
cholesterol (2:1) molar ratio were transferred into a round flask and dissolved in 19 mL of 
chloroform: methanol (2:1) molar ratio. One mL of ethanedithiol bismuth was then added to the 
round flask. The organic solvents were removed by using rotary vapor (Buchi Rotavapor R205, 
Buchi vacuum controller V-800; Brinkman, Toronto, Ontario, Canada) under vacuum at 55°C, 
which resulted in a thin layer of lipid. The lipid film was rehydrated by adding 12 mL of PBS 
with hand shaking for 5-7 min in a water bath at 55°C until it became a suspension. The 
suspension lipids were then sonicated at an amplitude of 50% (Sonic Dismembrator Model 500, 
Fisher Scientific, Ottawa, ON, Canada) for 10 min (40 sec ON and 5 sec OFF). Tobramycin (8 
mg/mL) and PG were added to the sonicated suspension. The solution was then sonicated again 
for 10 min (40 sec ON and 5 sec OFF). The sonicated liposomes were transferred to 15 mL tubes 
and frozen for 15 min at -70°C and then freeze-dried overnight (Freeze Dry System model 
77540, Labconco Corporation, Kansas City, MO, USA). The powdered liposomes were stored at 
0°C. To rehydrate the powder formulation, sterile distilled water was added in the volume of 
10% of the volume before lyophilisation, vortexed, and then the mixture was incubated for 30 
min at 45°C; then PBS was added to restore the original volume. The solution was centrifuged 
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(Beckaman L8-M Ultracenterifuge) for 20 min, at 100,000 ×g and 4°C and the supernatant was 
removed. This step was repeated by PBS as described previously (52). The size of liposomes was 
determined by a Submicron Particle Sizer, Model 270 (Nicomp, Santa Barbara, CA, USA). 
2.2.4. Tobramycin encapsulation efficiency (EE) within 
LipoBiEDT-TOB formulation 
The concentrations of tobramycin incorporated into LipoBiEDT were measured by an agar 
diffusion assay using laboratory strains of S. aureus (ATCC 29213) as an indicator organism for 
tobramycin. We used an overnight culture of the organisms in cation-adjusted Mueller-Hinton  
broth (CAMH) to prepare a bacterial solution equivalent to 0.5 McFarland (1.5×l0
8
 
bacterial/mL). The bacterial suspension in warm (45°C) Mueller-Hinton agar was then poured 
into a sterile glass plate (460 mm×360 mm) and left to solidify at room temperature. Wells of 5 
mm diameter were made with a well puncher. Standard curves of diluted tobramycin as well as 
samples of LipoBiEDT-TOB were prepared. Triplicate samples (25 µL) were transferred into the 
agar plate holes. The plate was covered and incubated for 18 h at 37°C. We then measured the 
inhibition zones and the averages of triplicate measures were used in data analysis. The standard 
curve was utilized to calculate concentrations of the entrapped tobramycin that were released 
from the liposomes by 0.2% (vol/vol) Triton X-100 (with PBS). The sensitivity of the assay was 
0.75 µg/ml. The quantifiable limit for tobramycin was 0.75 µg/ml. At concentrations from 0.75 
to 12.5 µg/ml, the coefficients of variation (ratio of standard deviation to the mean in percentage) 
ranged between 1.2 and 2.9%. Over the same concentrations, the intraday coefficients of 
variation ranged between 2.2 and 3.5%. For 10 samples of spiked tobramycin, the standard curve 
linearity extended over the range 0.75 to 12.5 µg/ml gave a correlation coefficient greater than 
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0.999. Concentration measurements were the means of at least three independent experiments, 
with each experiment measured in triplicate. 
2.2.4.1. Encapsulation efficiency 
The drug encapsulation efficiency (expressed as a percentage) was calculated by dividing the 
concentration of LipoBiEDT-TOB (determined by the microbiological assay as described in 
section 2.2.4.) by the concentration of free tobramycin used in the original preparation of these 
liposomes. 
2.2.5. Determination of the minimum inhibitory concentrations 
(MICs) 
The micro-broth dilution method was used to determine the MICs for tobramycin. Briefly, the 
reference strain S. aureus or clinical isolates of P. aeruginosa PA-489122 were exposed to 
different dilutions of LipoBiEDT-TOB or a combination of tobramycin with BiEDT. The 
contribution of bismuth-ethanedithiol to the MICs was assessed by exposing the aforementioned 
bacterial strains to different concentrations of BiEDT-TOB and LipoBiEDT-TOB, with a starting 
concentration of 128 mg/L for tobramycin as well as 128 µM for BiEDT in the LipoBiEDT-TOB 
and free BiEDT-TOB as reported previously (123). Drug-free bacterial cultures and an ABt broth 
medium alone were used as positive and negative controls respectively. 
2.2.6. Quantification of bismuth in liposomal formulations 
The bismuth content within the LipoBiEDT-TOB formulation was measured by graphite 
furnace atomic absorption spectroscopy (GFAAS) as described previously, with some 
modifications (52). To simplify, samples were lyophilized, weighed, and then transferred into 
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Teflon digestion vessels. A total of 1 mL H2O2 (30%, w/w) and 4 mL HNO3 was added and the 
samples were digested overnight at 25°C. Samples were then subjected to hot-plate digestion in a 
glycerol bath at 135–140°C for 3 h and left overnight. Next, the volumes were adjusted to 25 mL 
with double distilled water. 1.25 mL from each digested sample was then subjected to 20-fold 
dilution with 2% HNO3. Samples were then analyzed by GFAAS (AAnalyst 600, Perkin Elmer 
Precisely, Woodbridge, ON, Canada). 
2.2.7. Evaluation of QS and virulence factor production and 
activity 
PA-489122 was grown in ABt medium for 18 h at 37°C; then the bacteria solution was 
adjusted to follow the 0.5 McFarland standard (optical density at 600 nm [OD600], 0.13) in a 100 
ml flask and incubated for 1 h at 37°C for experiments involving QS signal molecules, lipase, 
chitinase, and protease. When the bacterial concentration doubled to OD600=0.26, the solutions 
were exposed to an equal volume of free or liposomal BiEDT-TOB (1/16-1/2 MICs). Untreated 
P. aeruginosa PA-489122 served as control. After 24 h, bacterial cultures were measured and 
centrifuged, at 16000 ×g for 15 min at 4°C and filter sterilized (0.22 µm). To test that there were 
no killing effect of the antibiotic on bacteria at concentrations below the MICs, free or liposomal 
BiEDT-TOB (1/4 and 1/2 MICs) was introduced to a PA-489122 culture that had been adjusted 
to 0.5 McFarland standard in 100 ml flasks and incubated at 37°C with agitation (250 rpm). The 
growth was monitored (OD600) for 8 h. 
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2.2.8. Bioassay for AHL production 
Supernatant samples were screened for AHL production as described previously with some 
modification (54). A. tumefaciens strain A136 (pCF218)(pCF372) (Ti
-
)  cells equal to density of 
10
6
 CFU/ml with β-D-galactopyranoside (20 mg/ml in dimethylformamide) and LB agar at 45°C 
were poured into Petri dishes. Wells of 5 mm diameter were made with a well puncher and 
aliquots (80 µl) from control or treated supernatant samples were transferred to the wells. The 
Petri dishes were incubated for 48 h at 30°C. AHL production levels were confirmed by blue 
pigmentation around the wells. 
2.2.9. β -Galactosidase activity assay 
The level of AHL production from P. aeruginosa exposed to free or LipoBiEDT-TOB at sub-
inhibitory concentrations was examined by measuring the ability of P. aeruginosa AHL 
signaling molecules released in the supernatants to activate the production of β-galactosidase in 
the reporter strain A. tumefaciens (A136) as described previously (55). Briefly, bioassay tubes 
containing 4 mL of reporter strain and 1 mL of supernatant were incubated at 30°C in water bath 
for 5 h with rotation at 100 r.p.m. Next, bacterial cell density was measured at (OD600) before 
centrifugation. The supernatants were removed, and the pellets were suspended in an equal 
volume of Z buffer (0.06 M Na2HPO4.7H2O, 0.04 M NaH2PO4.H2O, 0.01 M KCl, 0.001 M 
MgSO4.7H2O, 0.05 M β-mercaptoethanol, PH 7.0). The cells were then permeabilized by a 
solution of 200 µL of chloroform and 100 µL of 0.1 % sodium dodecyl sulphate prior to the 
addition of 0.4 mL of O-nitrophenol-β-D-galactopyranoside (4 mg/mL in PBS). After the 
development of yellow color, 1 mL of 1M Na2CO3 was added to stop the reaction. Optical 
density of the reaction samples was measured at 420 and 550 nm. Miller units of β-Galactosidase 
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were calculated as (1000× A420nm) ‒ (1.75× A550nm)/ (time × volume × A600nm) as described 
previously (56). 
2.2.10. Virulence factor assays 
Lipase activity was evaluated using Tween 20 as substrate. Briefly, the reaction mixture 
consisted of 0.6 mL of 10% Tween 20 in Tris buffer, 0.1 mL of 1 M CaCl2, 0.6 mL of filtered 
supernatant, and 1.6 mL of double distilled water. Samples were incubated at 37°C for 24 h with 
agitation (200 rpm). In the presence of lipase, Tween 20 is broken down to a fatty acid and 
alcohol. The fatty acid binds calcium to form a precipitate that was measured at (OD400). For 
chitinase, 1 mL of filtered supernatant was mixed with 1 mL of PBS and 5 mg of insoluble chitin 
azure. The reaction mixture was incubated at 37°C for 24 h with agitation (200 rpm). The 
cleaving of chitin azure in the presence of chitinase results in the release of a blue-coloured dye 
that can be measured spectrophotometrically at (OD290). The lipase and chitinase experiments 
were repeated three times with three replicates and the results were normalized by dividing the 
optical density by cell density (OD600). For the protease assay, 100 µL of filtered supernatants 
were transferred into the wells of an ABt medium containing 2 % agar and 2 % skim milk. Plates 
were incubated for 48 h at 37°C. Zones of clearance due to the proteolytic activity of protease 
could be easily perceived and were measured in (millimeters) by using digital callipers. The 
experiments were repeated three times with three replicates. 
2.2.11. Preparation of agar beads 
Agar beads were prepared as described previously with some modifications (57). The P. 
aeruginosa PA-489122 strain was grown overnight at 37°C in a tryptic soy broth. The bacteria 
were then embedded into agar beads by mixing 2% v/v of the aforementioned strain with tryptic 
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soy agar and mineral oil (1:3 volume ratio) at 45°C. The mixture was then vortexed vigorously 
and cooled down by placing crushed ice around the vessel while stirring continuously for 5 min. 
Next, the mineral oil was removed by centrifugation at slow speed for 5 min, 500×g at 4°C. Agar 
beads were washed once with 0.5% sodium deoxycholic acid, once with 0.25% sodium 
deoxycholic acid, and three times in PBS for 20 min, 1,000×g at 4°C. The number of bacteria 
was determined after homogenizing the bacteria-impregnated bead suspension. The bacterial 
count was ascertained by working 10-fold serial dilutions in phosphate-buffered saline (PBS) on 
Mueller-Hinton agar plates as described previously (58).  
2.2.12. Experimental infection and LipoBiEDT-TOB treatment 
Fifteen Sprague-Dawley rats weighing 201-225 g (Charles River, Saint Constant, Quebec, 
Canada) were used in this study. The animals were housed (Nalgene® cages) in groups of three 
for 1 week before any experiment was undertaken and allowed free access to food and water. 
Animals were kept at room temperature and were exposed to alternate cycles of 12 hours of light 
and darkness. Animals used in this study were treated and cared for in accord with the guidelines 
recommended by the Canadian Council on Animal Care and the Association for Assessment and 
Accreditation of Laboratory Animal Care. The experimental protocol was approved by the 
Institutional Animal Care and Use Committee. 
 To mimic the chronic respiratory tract infection caused by P. aeruginosa, PA-489122 was 
incorporated into agar beads. Animals were anesthetized with a mixture of 70 mg/kg of ketamine 
hydrochloride and 7 mg/kg of xylazine by intraperitoneal injection before infection and placed in 
the supine position, and the upper jaw was attached to the operating table with a rubber band 
brought over the incisor teeth. Using a laryngoscope, the tongue was moved aside and the mouth 
was opened. The larynx was identified and distinguished by its opening and closing as the rat 
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breathed. A catheter was inserted between the vocal cords and pushed gently forward into the 
trachea. The catheter’s insertion was confirmed by the formation of water condensation on a cold 
mirror with each breath of the rat. The rats were then inoculated with 50 µL of agar beads 
containing 10
6
 CFU of P. aeruginosa at the bifurcation of the trachea with a 1mL tuberculin 
syringe followed by a bolus of air to ensure complete delivery. 
Four days after the inoculation with agar beads, the rats were anaesthetized using the same 
procedure as above to be treated with antibiotics. The rats were sorted to three groups and each 
group was administered either saline, BiEDT-TOB or LipoBiEDT-TOB for three days. Infected 
animals received a dose (same method as described for infection) of either 300 mg/L of 
LipoBiEDT-TOB per kg or 300 mg/L of BiEDT-TOB per kg. The concentration of tobramycin 
in free or LipoBiEDT-TOB was 300 mg/L and BiEDT in liposomal as well as the combination 
with tobramycin was 300 µM. Saline (90 µL) was administered to the infected control animals. 
Twenty four hours after the last treatment, the animals were euthanized by using CO2. The 
kidneys and the lungs were removed aseptically and homogenized in cold sterile PBS (33% 
[wt/vol]) for 40 s with a Polytron Homogenizer. The homogenizer was rinsed, immersed in 95% 
ethanol, flamed, and then cooled down with cold saline between samples. Lung bacterial counts 
were performed after homogenizing the lungs. Serial 10-fold dilutions of the homogenates in 
cold PBS were made, and 0.1 mL of each dilution was pipetted and spread on Mueller-Hinton 
agar. The experiment was done in triplicate and the bacterial counts for each animal were done in 
triplicate. CFU were counted after 24 h incubations at 37°C and counts were expressed in log10 
CFU per pair of lungs. To measure the quantity of active tobramycin in tissues, the tissue 
samples were concentrated as follows: 1mL samples of homogenized lungs or kidneys were 
lyophilized (Freeze Dry System model 77540, Labconco Corporation, Kansas City, MO, USA) 
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and rehydrated with 100 µL of sterile PBS. The presence of active tobramycin was detected by 
an agar diffusion assay as described above in 2.4.  
2.2.13. IL-8 assay 
Supernatants from sera and the lung homogenates samples were used to quantify secreted IL-
8 protein. A 96-well plate was pre-coated with IL-8 capture antibody (primary antibody) 
overnight. A wash buffer, consisting of 1x PBS and Debecos buffered salts, was used between 
each step to rinse excess reagents from the treatment plate according to the manufacturer’s 
protocol (BioLegend, San Diego, CA). Next, the protein blocking agent was added to each well 
of the 96-well plate. The blocking agent was allowed to sit in the wells for one hour while on a 
shaker (200 rpm) at room temperature. The assay diluent was removed from plate with wash 
buffer. A standard curve was made with 1:2 serial dilution of known IL-8 antigen. Supernatants 
were spun in a microcentrifuge for 10 min, at 106 ×g and 22°C. The supernatants were added to 
the well for two hours while shaking. The plates were washed before adding the detection 
antibody for one hour on a shaker. Detection antibody was washed and Avidin-HRP was added 
to sit in well for thirty minutes while shaking in the dark. The Avidin-HRP was washed with 
wash buffer and tetramethylbenzidine substrate Solution C was added for 15 min in the dark 
without shaking. A 2N H2SO4 solution was added to the mixture to stop the reaction. The plate 
was read with the Beckman Coulter AD 340 microplate reader (Beckman, Brea, CA). Data were 
normalized and IL-8 concentrations reported in pg/mL. 
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2.2.14. Data analysis 
The data presented as mean ± S.E.M. of three independent experiments. Comparisons of 
groups were made by one-way analysis of variance (ANOVA) using InStat 3 from GraphPad 
(GraphPad Software Inc., Version 5.0) followed by a post t-test. Probability values of *P<0.05, 
**P<0.01 and ***P<0.001 are reported as statistically significant. 
2.3. Results 
2.3.1. LipoBiEDT-TOB characterization 
The average size of the LipoBiEDT-TOB formulation was 907.3 ± 40.1 nm and the 
encapsulated tobramycin in the LipoBiEDT formulation was 1.0 ± 0.2 mg/mL. The percentage of 
tobramycin that was encapsulated into liposomes 14.40 ± 0.001%. Atomic absorption analysis 
showed that the concentration of bismuth incorporated into LipoBiEDT-TOB formulation was 
1.0 ± 0.3 mM. 
2.3.2. Antimicrobial activity of free and LipoBiEDT-TOB 
The MICs of LipoBiEDT-TOB formulation against the P. aeruginosa strain used in this study 
was 16-fold lower than tobramycin alone or fourfold lower than tobramycin in combination with 
BiEDT. For example, the MIC of tobramycin alone was 16 mg/L, whereas BiEDT-TOB was 4 
mg/L for tobramycin and 4 µM for BiEDT in free BiEDT-TOB compared to 1 mg/L for 
tobramycin and 1 µM for BiEDT in LipoBiEDT-TOB. 
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2.3.3. Effect of sub-inhibitory concentrations of free or 
LipoBiEDT-TOB 
The effect of concentrations (1/4-1/2 MICs) of free BiEDT or LipoBiEDT-TOB on bacterial 
growth are shown in (Fig. 1). The rate of growth of cells was inhibited when treated with 1/2 of 
the MIC of the liposomal formulation, therefore this formulation at that concentration is not 
considered as sub-inhibitory for further investigation. Thus, all the experiments that involve QS 
and virulence factors were done using concentrations of 1/16-1/4 of the MICs of free or 
LipoBiEDT-TOB. 
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Figure 1: The effect of sub-inhibitory concentrations of BiEDT-TOB on the 
growth of PA-489122. Growth curve of P. aeruginosa without antibiotics (filled 
circles), in the presence of sub-inhibitory concentrations of 1/2 MIC of 
LipoBiEDT-TOB [ 0.5 mg/L of TOB][0.5 µM of BiEDT] (open circle), 1/4 MIC of 
LipoBiEDT-TOB [0.25 mg/L of TOB][0.25 µM of BiEDT] (filled triangle), 1/2 
MIC of free BiEDT-TOB [ 2 mg/L of TOB][2 µM of BiEDT] (filled squares), or 
1/4 MIC of free BiEDT-TOB [ 1 mg/L of TOB][1 µM of BiEDT] (open triangle). 
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2.3.4. QS molecule reduction 
P. aeruginosa PA-489122 was grown in an ABt medium for 24 h at 37°C with or without free 
or liposomal BiEDT-TOB at 1/16-1/4 MICs. Both formulas have reduced AHL production up to 
1/16 MIC compared to control, but did not prevent the production completely (Fig. 2). However, 
LipoBiEDT-TOB reduced AHL production at sub-inhibitory concentrations that were 4 times 
lower than for free BiEDT-TOB. At 1/4 MICs of free BiEDT-TOB, the production of the blue 
pigment ring around the edge was darker and more clear than 1/4 MIC of LipoBiEDT-TOB.  
 
 
Figure 2: Effect of sub-inhibitory concentrations of free or LipoBiEDT-TOB 
(1/16-1/4 MICs) on QS. LB agar containing Agrobacterium tumefaciens and 
β-D-galactopyranoside was poured in Petri dishes. Holes were made in the 
agar by a vacuum device and 80 µl from control or treated supernatant 
samples were transferred to the wells. The plates were incubated for 48 h at 
30ºC. 
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2.3.5. AHL quantification  
The levels of β-galactosidase activity, in response to AHL, indicated a decrease in the levels 
of AHL signaling molecules released from P. aeruginosa cells exposed to LipoBiEDT-TOB 
(Fig. 3a and b). For instance, free BiEDT-TOB at 1/8 MIC did not reduce the level of AHL 
significantly, whereas LipoBiEDT-TOB reduced the level of AHL, at 1/8 MIC significantly 
(P<0.01) compared to the control. LipoBiEDT-TOB was significantly more active in reducing 
AHL production than free BiEDT-TOB at 1/4 MIC (P<0.001). 
2.3.6. Reduction of virulence factors by BiEDT-TOB 
We compared the effects of free and liposomal BiEDT-TOB at 1/16-1/4 MICs on production 
of the virulence factors, lipase, chitinase, and protease by PA-489122. For the lipase assay, free 
BiEDT-TOB at 1/4 of the MICs did not reduce the production of lipase significantly compared to 
the control (Fig. 4a). LipoBiEDT-TOB at 1/4 MIC attenuated lipase production significantly 
compared to the control (P<0.001) (Fig. 4b). Chitinase production in the supernatants was 
evaluated by quantifying the breakdown of chitin azure. As shown in (Fig. 5a and b), the 
liposomal formulation was able to reduce chitinase at a concentration 8 times lower than with 
free BiEDT-TOB (1/8 vs. 1/4) and more effectively (P<0.01) than the free formulations. The 
activity of extracellular protease LasA in filtered sterilized supernatants was measured in agar 
plates containing 2% skim milk. Free BiEDT-TOB reduced the protease level at 1/4 of the MICs 
(P<0.01) compared to the control, whereas LipoBiEDT-TOB attenuated activity significantly at 
1/4 MIC (P<0.001). Furthermore, protease activity was able to be reduced by LipoBiEDT-TOB 
at a concentration eightfold lower than the free formulation (1/8 vs. 1/4) (P<0.001) as indicated 
in (Fig. 6a and b). 
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Figure 3: Production of the QS molecules as measured by β-galactosidase 
activity: (a) in the presence of free BiEDT-TOB or (b) in the presence of 
LipoBiEDT-TOB at 1/16 -1/4 MICs. P. aeruginosa was exposed to free and 
LipoBiEDT-TOB then the supernatants were collected and incubated with A. 
tumefaciens (A136). β-Galactosidase activities were measured in miller units. 
Each bar represents the mean ± S.E.M. of three independent experiments. P 
values were considered significant when compared with the control and between 
groups: ***P<0.001, **P<0.01, and *P<0.05. 
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Figure 4: Lipase activities in supernatant from PA-489122. Cultures grown either 
without antibiotics as control and (a)  in the presence of 1/4 MIC of free BiEDT-
TOB[1 mg/L of TOB][1 µM of BiEDT], 1/8 MIC of free BiEDT-TOB[0.5 mg/L of 
TOB][0.5 µM of BiEDT] or 1/16 MIC of free BiEDT-TOB[0.25 mg/L of TOB][0.25 
µM of BiEDT] or (b) in the presence of 1/4 MIC of LipoBiEDT-TOB[0.25 mg/L of 
TOB][0.25 µM of BiEDT], 1/8 MIC of LipoBiEDT-TOB[0.125 mg/L of TOB][0.125 
µM of BiEDT], 1/16 MIC of LipoBiEDT-TOB[0.062 mg/L of TOB][0.062 µM of 
BiEDT]. Each bar represents the mean ± S.E.M. of three independent experiments. 
P value was considered significant when compared with the control: ***p<0.001. 
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Figure 5: Chitinase activities in supernatant from PA-489122. Cultures grown 
either without antibiotics as control and (a)  in the presence of 1/4 MIC of free 
BiEDT-TOB[1 mg/L of TOB][1 µM of BiEDT], 1/8 MIC of free BiEDT-TOB[0.5 
mg/L of TOB][0.5 µM of BiEDT] or 1/16 MIC of free BiEDT-TOB[0.25 mg/L of 
TOB][0.25 µM of BiEDT] or (b) in the presence of 1/4 MIC of LipoBiEDT-
TOB[0.25 mg/L of TOB][0.25 µM of BiEDT], 1/8 MIC of LipoBiEDT-
TOB[0.125 mg/L of TOB][0.125 µM of BiEDT], 1/16 MIC of LipoBiEDT-
TOB[0.062 mg/L of TOB][0.062 µM of BiEDT]. Each bar represents the mean ± 
S.E.M. of three independent experiments. P values were considered significant 
when compared with the control and between groups: ***P<0.001, **P<0.01. 
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Figure 6: Protease activities in supernatant from PA-489122. Cultures grown 
either without antibiotics as control and (a)  in the presence of 1/4 MIC of free 
BiEDT-TOB[1 mg/L of TOB][1 µM of BiEDT], 1/8 MIC of free BiEDT-TOB[0.5 
mg/L of TOB][0.5 µM of BiEDT] or 1/16 MIC of free BiEDT-TOB[0.25 mg/L of 
TOB][0.25 µM of BiEDT] or (b) in the presence of 1/4 MIC of LipoBiEDT-
TOB[0.25 mg/L of TOB][0.25 µM of BiEDT], 1/8 MIC of LipoBiEDT-TOB[0.125 
mg/L of TOB][0.125 µM of BiEDT], 1/16 MIC of LipoBiEDT-TOB[0.062 mg/L of 
TOB][0.062 µM of BiEDT]. Each bar represents the mean ± S.E.M. of three 
independent experiments. P values were considered significant when compared 
with the control and between groups: ***P<0.001, **P<0.01. 
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2.3.7. LipoBiEDT-TOB or BiEDT-TOB activity against infected 
rats lungs 
The number of bacteria loaded in agar beads was 8.4 ± 0.1 log10 CFU/mL. We instilled a total 
of 10
6
 CFU
 
in 50-µL volume in the lungs of each rat. The number of CFU enumerated following 
24 h of the last treatment with saline was 7.4 ± 0.2 log10 CFU/lungs. The bacterial load in the 
lungs of the rats after three doses of 300 µg for tobramycin and 300 µM for BiEDT in free or 
liposomal formula was significantly lower (P<0.001) than the control (Fig. 7). The effect of 
liposomal formulation in lowering bacterial load was significantly higher than that of the free 
formulation (3.1 ± 0.1 log10 CFU/lungs vs. 4.7 ± 0.3 log10 CFU /lungs; P<0.001) as shown in Fig. 
7. 
 
2.3.8. Levels of active antibiotic in the lungs, the kidneys and the 
sera of treated rats 
The tobramycin concentration was 25.1 ± 1.5 µg/mg of lungs after 24 h of administering the 
last doses of LipoBiEDT-TOB. We did not detect tobramycin in the kidneys or sera of the rats 
treated with the liposomal formulation. In addition, we did not detect any active tobramycin in 
the lungs or sera, but we found 6.5 ± 5.3 µg/mg tobramycin in the kidneys of the rats treated with 
free BiEDT-TOB (Fig. 8). 
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Figure 7: Effect of free BiEDT-TOB or LipoBiEDT in chronic lung infection 
model. Rats were inoculated with agar beads containing 10
6
 CFU of 
Pseudomonas aeruginosa. After the bacteria were grown for four days, saline 
(filled circles) as well as free BiEDT-TOB (open squares) or LipoBiEDT-TOB 
(filled triangle) was intratracheally-administered at 300 µg/mL/kg for three 
days. Lungs were then harvested and homogenized for analysis. Each column 
represents mean ± S.E.M. of four animals. P values were considered significant 
when compared with the control as well as between groups ***P<0.001. 
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Figure 8: Measurement of active tobramycin. Tobramycin concentrations in the 
lungs and the kidneys homogenates of rats chronically infected with P. aeruginosa 
were evaluated by microbiological assay. Tissues were removed at 24 h after that 
last treatment of LipoBiEDT-TOB (filled bar) or free BiEDT-TOB (clear bar). 
Bars represent the mean ± S.E.M. of four animals. 
 
2.3.9. Effect of LipoBiEDT-TOB on IL-8 production 
We investigated whether LipoBiEDT-TOB would reduce the level of IL-8. In the lungs, the 
level of IL-8 decreased from 72.9 ± 28.8 pg/mL for the group treated with saline to 9.5 ± 1.3 and 
to 6.9 ± 2.1 pg/mL in groups treated with LipoBiEDT-TOB and free BiEDT-TOB, respectively 
(Fig. 9a). Free BiEDT-TOB slightly reduced IL-8 released in sera to 34.3 ± 14.8 pg/mL 
compared to 58.8 ± 9.9 pg/mL measured in sera for the saline-treated group whereas only 0.4 ± 
0.3 pg/mL of IL-8 was detected in sera of LipoBiEDT-TOB treated animals (Fig. 9b). 
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Figure 9: The concentration of IL-8: (a) in lungs and (b) in sera of rats infected 
with P. aeruginosa by enzyme-linked immunosorbent assay (ELISA). Each 
column represents mean ± S.E.M. of four animals. 
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2.4. Discussion 
Many studies described the efficacy of inhaled tobramycin on lowering P. aeruginosa 
pulmonary infection in CF patients (59). The high dose required and the prolonged use of 
tobramycin raise investigators’ concerns about its toxicity. Encapsulation of antimicrobial agents 
in liposomes has been proven to increase their efficacy (60, 61). Bismuth has emerged as a 
therapeutic agent against gastrointestinal infection caused by H. pylori (62). Introducing BiEDT 
at a sub-inhibitory concentration resulted in reducing alginate and lipopolysaccharide production, 
as well as inhibition of adherence of P. aeruginosa to epithelial cells and secretion of virulence 
factors (47). Furthermore, previous results from our laboratory indicated that co-encapsulation of 
BiEDT into liposomal-loaded tobramycin increases the killing effect on P. aeruginosa, as well as 
diminishing AHL production and bacterial adherence to human lung epithelial cells (52, 53). 
Herein, we have demonstrated that LipoBiEDT-TOB at sub-inhibitory concentration is able to 
debilitate QS signaling molecule production and secretion of virulence factors, including 
protease, chitinase and lipase in vitro. In addition, we examine in vivo bactericidal efficacy and 
the anti-inflammatory property of LipoBiEDT-TOB in a rat model of pulmonary infection. 
The MIC results reported here indicate significant differences between free and liposomal 
BiEDT-TOB. The MIC of LipoBiEDT-TOB was 16-fold lower than the MIC of tobramycin 
alone and fourfold lower than the MIC of free BiEDT-TOB. These values are in agreement with 
previous observation on improved susceptibility of resistant Gram-negative strains to liposomal 
polymyxin B (60). Since exposing bacteria to the sub-inhibitory concentration of free or 
LipoBiEDT-TOB did not prevent P. aeruginosa to grow (Fig. 1), we investigated their potential 
effect on inhibition of clinical isolate P. aeruginosa communication and virulence factor 
production. The secretion of AHL molecules that play an important role in regulating the 
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production of several virulence factors was reduced compared to the control at both free and 
LipoBiEDT-TOB up to 1/16 MICs (Fig. 3). LipoBiEDT-TOB was able to reduce AHL 
production 29% at 1/8 MIC, whereas production was reduced 19% by free BiEDT-TOB at 1/8 
MIC compared to the control. Exposing P. aeruginosa to free BiEDT-TOB at 1/4 MIC showed 
50% reduction in AHL, whereas LipoBiEDT-TOB at 1/4 MIC led to an approximate 71% 
reduction compared to the control. However, comparing free and liposomal formulations, 
LipoBiEDT-TOB was found to be more effective at concentrations four times lower than free 
BiEDT-TOB based on qualitative (Fig. 2) and quantitative measurements (Fig. 3). Studies have 
reported that tobramycin at sub-inhibitory concentrations was able to decrease N-3-oxo-
dodecanoylhomoserine lactone and N-butanoylhomoserine lactone once tobramycin gains access 
to interact with bacterial ribosome (36, 37). Another study reported the improved efficacy of 
tobramycin with BiEDT in liposomes (53); thus, LipoBiEDT-TOB provides greater advantage in 
reducing 3-oxo-dodecanoylhomoserine lactone and N-butanoylhomoserine lactone production 
levels by enhancing tobramycin penetration into the cell to interact with ribosomes. This 
interaction might result in down-regulation of the QS gene (36).     
LipoBiEDT-TOB also reduced the level of virulence factors including lipase (Fig. 4), 
chitinase (Fig. 5), and protease (Fig. 6) at a concentration four to eight times lower than free 
BiEDT-TOB with respect to the corresponding untreated control levels. It is not yet clear, 
however, how LipoBiEDT-TOB exerts its effect to reduce virulence factors. Tobramycin inhibits 
protein synthesis in P. aeruginosa (36). BiEDT is known to inhibit alginate and 
lipopolysaccharides, as well as causing blebbing of the P. aeruginosa cell wall (47). 
Furthermore, transmission electron microscopy has provided evidence of the fusion of 
LipoBiEDT-TOB and the penetration of tobramycin into the cell wall of P. aeruginosa (63). 
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Collectively, BiEDT in liposome form facilitates the uptake of loaded antibiotic, and it might 
thereby promote down-regulation of QS and virulence factors gene expression or reduce their 
post-transcription synthesis (63).  
Many investigators have reported intratracheal administration of liposome-loaded drugs such 
as deguelin (64), insulin (65), tobramycin (66), siRNA, antisense oligonucleotides, and 
anticancer drugs (67) into the lungs of rodents. The liposomal delivery system and intratracheal 
route satisfy three therapeutically preferred goals in pulmonary infection: (i) sustained release of 
an antibiotic from liposomes, which increases the residence time of the drug; (ii) reduction of 
antibiotic toxicity; (iii) direct aiming of the drug at the site of infection. The data reported here 
manifest that chronic respiratory infection caused by P. aeruginosa can be decreased by in situ 
administration of liposome co-encapsulated BiEDT and tobramycin. Three treatments of 
LipoBiEDT-TOB (300 mg/L/kg for tobramycin and 300 µM/kg for BiEDT) reduced P. 
aeruginosa in the lungs. We used a clinical isolate strain embedded in agar beads to initiate a 
chronic lung infection. Such retention apparently prevents physical elimination of bacteria and 
ensures stimulation of host defense typical of CF. Bacterial counts in the lungs showed 2.7 log10 
units reduction in CFU of the free BiEDT-TOB treated group compared to the control, whereas 
LipoBiEDT-TOB reduced the bacterial counts approximately by 4.3 log10 units compared to the 
control. The increased efficacy of LipoBiEDT-TOB can be explained by the enhanced 
penetration of encapsulated formula through the bacterial outer membrane, likely through the 
mechanism of fusion (60). Previous work by others has shown improved bactericidal activities of 
liposome-encapsulated antibiotics specific to P. aeruginosa (68, 69).  
The microbiological analysis of the liposomal antibiotic in the lungs indicated the presence of 
25 times the MIC of active tobramycin after 24 h of antibiotic therapy. However, no active 
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tobramycin was detected at 24 h when the animals were treated with the free drug. Despite the 
fact that 25 times the MIC was detected in the lungs, the animals’ lungs treated with 
LipoBiEDT-TOB remained infected. A previous study speculated that the persistent infection 
with liposomal antibiotic treatment might be due to the high stability of the liposomes’ lipid 
composition, the protection of bacteria by agar beads, or a portion of the agar beads injected 
being preserved in the bronchial tree (58). Since our formula consists of DSPC and cholesterol 
with a phase transition temperature of 55°C (70), the high stability of the vesicle might not allow 
the release of tobramycin at sufficient concentration to ensure a complete eradication. Also, 
using agar beads to induce chronic infection might contribute to the presence of infection. The 
microbiological assay also showed no active tobramycin in the kidneys of the LipoBiEDT-TOB 
treated group, but we found tobramycin accumulation in the kidneys of the free BiEDT-TOB 
treated group. There was no active tobramycin detected in plasma when the antibiotic was 
administered in liposomes. Our findings agree with previously published reports (58, 71) and 
with the notion that the half-life of tobramycin in sera of human and rodents is around 2 h after 
intravenous and intratracheal administration (58, 72). Likewise, our liposomal formulation 
results are in agreement with data reported by other researchers who investigated the efficacy of 
liposomal antibiotics against P. aeruginosa respiratory infection (73, 74) and this could suggest 
an advantage in reducing the nephrotoxicity associated with tobramycin treatment (73). 
Tobramycin is known to have both antibacterial and anti-inflammatory activity (75, 76). Our 
results indicate the benefit of administrating LipoBiEDT-TOB intratracheally on P. aeruginosa 
infection and showed lowered inflammation by reduced IL-8 levels in lungs and sera. Although 
the exact mechanism of tobramycin as an anti-inflammatory drug is not well known, tobramycin 
have been shown to protect epithelial lung cells against myeloperoxidase by binding to anionic 
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cell surfaces and neutralizing hypochlorous acid that participate in tissue damage (77, 78). 
However, since the local inflammatory response is in agreement with pulmonary infection (79), 
the significant decrease in the P. aeruginosa counts in lungs may be explained by the beneficial 
aspects of LipoBiEDT-TOB. 
In conclusion, LipoBiEDT-TOB modulated the production of QS molecules, virulence factors 
and IL-8 and could highly enhance the treatment of chronic pulmonary infection in CF patients. 
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Chapter 3 
3.1. Conclusion 
Chronic pulmonary infection caused by Gram-negative Pseudomonas aeruginosa is the 
main cause of morbidity and mortality among Caucasians with CF. Pseudomonas aeruginosa 
regulates its gene expression and virulence factors through cell-to-cell communication molecules 
to colonize the lung successfully. Tobramycin, an aminoglycoside antibiotic, is the most 
effective regimen of treatment; however, due to its elevated toxicity profile and the increased 
resistance of Pseudomonas aeruginosa to currently available antibiotics, a carrier system such as 
liposomes is required to improve bactericidal activity and reduce toxicity. 
 Liposomes have also drawn great interest from research scientists as a suitable model for 
the investigation of the structure and function of biological membranes. Several of the 
liposomes’ biological and physicochemical properties including biocompatibility and 
biodegradability contribute to their success in the pharmaceutical industry. Furthermore, 
encapsulated agents in liposomes can be protected from the host’s metabolic enzymes and other 
internal environmental elements. Liposomes can also prolong the drug’s effect by providing a 
sustained release of the bioactive compound in the body. In addition, they can be administered 
through different routes depending on the affected body system. Most importantly, they can 
carry any compound regardless of their chemical affinity as hydrophilic drugs can be 
encapsulated in the aqueous core, whereas lipophilic agents are carried within the lipid bilayers. 
The ability of liposomes to co-encapsulate hydrophobic as well as hydrophilic chemicals 
facilitates development of synergistic therapeutics. Recent studies showed the superiority of 
liposomal encapsulated bismuth-ethanedithiol and tobramycin formulation against Pseudomonas 
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aeruginosa. The main objective of this study was to evaluate the efficacy of LipoBiEDT-TOB in 
vitro and in vivo.  
We demonstrated that LipoBiEDT-TOB, below the bactericidal concentration, reduced 
QS signaling molecules produced by P. aeruginosa compared to the untreated samples and 
exhibited four times higher activity than the free formulation. LipoBiEDT-TOB also 
significantly decreased the level of virulence factors-secreted enzymes including lipase, chitinase 
and protease at an encapsulated tobramycin concentration eight times lower than that of free 
tobramycin in vitro. 
Intratracheal administration of LipoBiEDT-TOB into the infected lungs of rodents 
resulted in the presence of the active agents at 25 times higher the concentration required to 
inhibit the bacteria. In other words, the liposomal BiEDT formulation improved the antimicrobial 
activity of tobramycin and provided a sustained, as well as direct, release of antibiotic at the site 
of infection. Furthermore, the liposomal formulation provided an advantage in reducing the 
nephrotoxicity associated with aminoglycoside treatments. Administration of LipoBiEDT-TOB 
also showed a beneficial reduction of inflammatory response by reducing IL-8.  
This research demonstrates the increase efficacy of bactericidal agents such as bismuth- 
ethanedithiol when they are encapsulated in a liposomal formulation while reducing its adverse 
side effects.  
3.2. Future directions        
We have examined the efficacy of liposomal formulations on cell-to-cell communication 
and secreted virulence factors in vitro; however, their exact mechanism of action on reducing QS 
and virulence factors has not been fully explored yet. Thereby, investigation of the antimicrobial 
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effectiveness on P. aeruginosa gene expressions, which are involved in production signaling 
molecules and virulence factors in vivo, could explain this mechanism. 
A single dose of LipoBiEDT-TOB against chronic pulmonary infection caused by P. 
aeruginosa was investigated and showed an improvement in the pharmacokinetic and efficacy 
against infection. However, it would be important to test in future work the efficacy of a multiple 
dose regimen to determine whether or not this would eliminate bacterial infection completely. 
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